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Extracorporeal photopheresis (ECP) is an effective, low-risk
immunomodulating therapy for leukemic cutaneous T cell lymphoma (L-CTCL)
and graft versus host disease (GVHD), but whether the mechanism(s) of action
in these two diseases is (are) identical or different is unclear. To determine the
effects of ECP in vivo, we studied regulatory T cells (T-regs), cytotoxic T
lymphocytes (CTLs), and dendritic cells (DCs) by immunofluorescence flow
cytometry in 18 L-CTCL and 11 GVHD patients before and after ECP at Day 2, 1
month, 3 months, and 6 months. In this study, ECP was effective in 12/18 LCTCL patients with a 66.7% overall response rate (ORR) and 6/11 GVHD
patients with a 54.5% ORR. Prior to ECP, the percentages of CD4+Foxp3+ T
cells in 9 L-CTCL patients were either lower (L-CTCL-Low, n=2) or higher (LCTCL-High, n=7) than normal. Five of the 7 GVHD patients had high
percentages of CD4+Foxp3+ T cells (GVHD-High). Six of 7 L-CTCL-High patients
had >80% CD4+Foxp3+ T cells which were correlated with tumor cells, and were
responders. Both L-CTCL-High and GVHD-High patients had decreased
percentages of CD4+Foxp3+ and CD4+Foxp3+CD25- T cells after 3 months of
treatment. CD4+Foxp3+CD25+ T cells increased in GVHD-High patients but
decreased in L-CTCL-High patients after 3 months of ECP. In addition, numbers
of CTLs were abnormal. We confirmed that numbers of CTLs were low in LCTCL patients, but high in GVHD patients prior to ECP. After ECP, CTLs
increased after 1 month in 4/6 L-CTCL patients whereas CTLs decreased after 6
vi

months in 3/3 GVHD patients. Myeloid (mDCs) and plasmacytoid DCs (pDCs)
were also low at baseline in L-CTCL and GVHD patients confirming the DC
defect. After 6 months of ECP, numbers and percentages of mDCs and pDCs
increased in L-CTCL and GVHD. MDCs were favorably increased in 8/12 LCTCL responders whereas pDCs were favorably increased in GVHD patients.
These data suggest that ECP is favorably modulating the DC subsets. In LCTCL patients, the mDCs may orchestrate Th1 cell responses to overcome
immune suppression and facilitate disease regression. However, in GVHD
patients, ECP is favorably down-regulating the immune system and may be
facilitating immune tolerance to auto-or allo-antigens. In both L-CTCL and GVHD
patients, DCs are modulated, but the T cell responses orchestrated by the DCs
are different, suggesting that ECP modulates depending on the immune milieu.
_______________
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CHAPTER 1
GENERAL BACKGROUND
1.1 Elements of the Immune System
The immune system is comprised of differentiated hematopoeitic cells that
arise from bone marrow hematopoietic stem cells (HSC) (Figure 1.1). HSCs
differentiate into various types of cells such as erythroid cells, platelets, myeloid
cells such as neutrophils, basophils, eosinophils, monocytes, mast cells, natural
killer cells, dendritic cells, natural killer T cells, and thymus derived cells (T cells),
and B cells depending on the environment and stimuli [1]. For example, the
HSCs that migrate to the thymus can develop into T cells where thymic
epithelium –HSC interaction leads to deletion of naive T-cells recognizing selfantigens and promotes survival of other T-cells that will become part of the
intrinsic host response to neo-antigens. After development, immune cells
orchestrate host protection by responding against foreign antigens. For these
reactions to occur normally, a proper maintenance of molecular and cellular
balance is vital. Once awry, normal immunity is disrupted and disease with
increased susceptibility to infection arises.

1

Figure 1.1. Simplified schematic of immune cell development.
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1.2 Innate and Adaptive Immunity
Host defenses against pathogens are organized into two categories: 1)
Innate and 2) Adaptive Immunity (Figure 1.2). Innate immunity is the fast-acting,
front-line defense against all pathogens and is non-specific. Adaptive immunity
is activated by innate immunity and is a slow, antigen-specific response that can
lead to formation of memory against foreign antigen.
Innate immunity comprises of surface tissues such as the skin and
intestinal tract, molecules such as Toll-like receptors (TLRs), and cells including
neutrophils, macrophages, eosinophils, and dendritic cells. The first line of
defense in innate immunity includes the surface tissues which provide an
inpenetrable barrier to the environment. The skin, intestinal tract, respiratory
tract, and reproductive tract epithelia interact with the external environment and
continuously encounter bacteria, fungi, viruses, and pathogenic parasites. As a
result, these epithelia produce a diverse aramentium of antimicrobial proteins
that can kill or inhibit microbial growth to manage the substantial microbial
exposure. In addition, these surface tissues are challenged with defending a
large surface area against pathogens while maintaining homeostasis of
communities of commensal microorganisms. To cope with microbial challenges,
epithelial antimicrobial proteins (AMP) are produced and protect mammalian
body surfaces. AMPs are natural antibiotics that function to kill or inactivate
microorganisms [2]. Defensins, cathelicidins, lysozyme, C-type lections (i.e.
regenerating islet derived protein (REG) family, ribonucleases (RNAses,
angiogenin 4 (ANG4), and S100 proteins (calprotectin, and psoriasin (S100A7)
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are all distinct AMP protein families found in the skin and gut [2,3]. The physical
surface tissues coupled with AMPs produced by epithelial cells provide a barrier
to prevent pathogenic invasion. When pathogens evade anti-pathogenic
defense, protection is activated at the molecular and cellular level. Phagocytic
cells work quickly to contain the spread of invaders by sensing microbial
components through Toll-like receptors (TLRs) as well as cellular pinocytosis and
phagocytosis [4]. Neutrophils, macrophages, eosinophils, and dendritic cells
(DCs) are types of phagocytic cells that can detect pathogens. In addition to
their phagocytic capability, dendritic cells also express TLRs which can bind
bacterial components such as Flaggellin or LPS found on gram-postive bacteria
and gram-negative bacteria. This elicits an intracellular signaling casade that
enhances cytokine secretion, upregulation of MHC and co-stimulatory molecules,
and presentation of antigens.
Not only do DCs play a role in innate immunity, but they also have a role
in adaptive immunity. They “bridge” innate and adaptive immunity by activating B
and T cells through antigen presentation on their cell surfaces [5]. When B cells
are triggered by DCs, a humoral response containing secretion of antigen
specific antibodies occurs. At the same time, DCs activate CD4+ helper and
CD8+ T cells that elicit T cell responses specific to the antigen [6]. Depending on
the type of antigen, different CD4+ T helper responses such as Th1, Th2, Th17,
and T-reg can occur. Corresponding Th cells also secrete cytokines that
promote cell interactions with other cells which are recruited to the infected site.
For example, the Th1 response is mediated by CD4+ helper T cells and CD8+ T
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cells that secrete IFN-γ, IL-2, and IL-12 to fight against viruses. The CD4+ helper
cells “help” to elicit a cytotoxic attack against the virus, mainly through CD8+
cytotoxic T cells [7,8] .

5

Figure 1.2. Diagram of cells involved in innate and adaptive
immunity.
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1.3 Dendritic Cells
The architecture of the immune system includes a wide variety of cells that
help to maintain homeostasis. The balance between tolerance and immunity is
tightly controlled by professional antigen presenting cells (APCs). Professional
APCs have antigen-uptake machinery and MHC class II-peptide complexes on
the cell surface and can elicit T or B cell responses. Dendritic cells (DC) are a
type of professional APCs derived from hematopoietic precursors and have the
capability to induce antigen-specific T or B cell responses. First discovered in
the spleen about 40 years ago by Ralph Steinmen, DCs delineate from the
common myeloid progenitors, develop through the lymphoid pathway, and
differentiate from monocytes [9]. They exist in all lymphoid, non-lymphoid
tissues, and circulate in blood. Their ubiquitious presence allows them to sample
the environment through pattern recognition receptors (PPRs) such as TLRs or
phagocytosis. Through phagocytosis, DCs process antigens for cell surface
presentation to alert the other defense cells. Antigen presentation induces
upregulation of co-stimulatory molecules such as B7 family molecules (e.g.
CD80, CD86) and MHC molecules which allow interaction with multiple T cells
and B cells in the periphery or in the lymph nodes [10] .
The interactions between DC MHC chains and co-stimulatory molecules
with the T cell or B cell receptors initiates naïve T and B cell intracellular
signaling that induces a primary immune response that result in extracellular
cytokine secretion, extracellular and/or intracellular changes, and cellular
differentiation (Figure 1.3). Upregulation of stimulatory and MHC molecules on

7

DCs mark their transition from immature DCs to mature DCs status. Naïve T
cells become differentiated and acquire specificity in their response against the
foreign antigen. Naïve B cells also become differentiated into plasma cells that
produce and secrete antibodies targeted against the foreign antigen [11].
Although the DC family is heterogenous, it consists of different subsets
that each have specific functional characteristics. Two subsets that have been
characterized in humans are myeloid DCs (mDC) and plasmacytoid DCs (pDC).
The two subsets are distinguished by distinct expression of cell surface
molecules and PPRs which determine their specialized functions. Myeloid DC
(mDC) are CD11c+ cells expressing myeloid markers (e.g. CD13, CD33, and
CD11b). There are three subtypes of mDCs which can be identified by the
expression of CD11c in combination with unique surface molecules CD1c
(BDCA1), CD141 (BDCA3), and CD16 [12]. Immature mDCs reside in peripheral
tissues and migrate to lymph nodes after their maturation during infection or
inflammation to activate T cells and secrete IL-12 [13,14]. Plasmacytoid DCs
(pDC) produce large amounts of type 1 IFNs in response to bacterial or viral
stimuli. The high levels of type 1 IFNs enable communication between pDCs
and mDCs, natural killer cells, and B cells. These IFNs stimulate mDCs to
enhance T-cell activation and activate natural killer and B cells. During infection,
single-stranded viral RNA or unmethylated CpG DNA motifs are recognized by
TLR-7 and TLR-8, respectively, which are located in intracellular endosomes and
lysosomes. In steady-state conditions, pDCs circulate through the body after
entering the bloodstream and migrate to secondary lymphoid organs through
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high endothelial venules. After inflammation, pDCs accumulate at the infectious
site to take up antigens and then migrate to the lymph nodes to present the
encountered antigen [15,16].
PDCs are CD11c- cells without myeloid markers but with plasmacytoid
morphology, a well-developed Golgi apparatus, and rough endoplasmic
reticulum. Although mDCs possess myeloid markers and pDCs do not, their
developmental pathways remain unclear but cannot be categorized by the
conventional myeloid or lymphoid pathway [17]. Therefore, it is challenging to
identify mDCs and pDCs by lineage markers. The current method of identifying
mDCs and pDCs by extraceullar immunofluorescence flow cytometry is by
excluding lineage markers for other cells (CD3, CD14, CD16, CD19, CD20,
CD56), while detecting expression of HLA-DR (MHC II), and CD11c or CD123
(IL-3Rα ). Thus, mDCs are identified in this dissertation as Lineage-, HLADR+CD11c+ and pDCs are identified as Lineage-HLA-DR+CD123+.

9

Figure 1.3. Adaptive Immunity: DC and T cell interactions. Reprinted
by permission from Macmillan Publishers Ltd: Nature Reviews
Immunology, [18], copyright (2004).
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1.4 T cells
T cells delineate from HSCs and mature in the thymus. Expression of self
antigens in the thymic epithelium provides proper T cell education and
development. T cells interact with DCs or thymic epithelial cells for instruction of
proper function. Through a process termed negative selection, naïve T cells are
tested against protein chains found on conjugate cells called major
histocompatibility complexes (MHC). MHC I presents the self peptide and is
found on all cells and distinguishes all cells as “self”. It is vital that T cells do not
strongly react with MHC I + self peptide, otherwise autoimmunity would occur.
Thus, during developmental negative selection, T cells that do react to “self”
antigens are deleted whereas T cells that do not react with “self” are retained and
further differentiate into functionally distinct T-cell subgroups which react to and
produce different cytokine profiles [19].
Although there are natural killer T cells and γδ T cells, two major types of
αβ T cells include the CD4+ T helper (Th) and CD8+ cytotoxic T lymphocytes.
CD4 and CD8 are surface molecules that are part of the T-cell receptor
complexes which facilitate binding to MHC II or I on CD4+ or CD8+ cells,
respectively [20,21] (Figure 1.3).
Multiple types of CD4+ T helper cells exist. Naïve T cells can differentiate
into distinct CD4+ lineages such as Th1, Th2, Th17, T-reg, and Tfh based on
transcription factors and cytokines (Figure 1.4A). The differentiation of CD4+ Th
cells was previously viewed as inconvertible linear developmental pathways;
however more recently, current studies have challenged this classical view
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suggesting that differentiated Th cells can change into other types of Th cells
(Figure 1.4B) [22].

12

Figure 1.4. CD4+ Th cell differentiation. A) Classical view of Th differentiation:
Differentiation pathways are not convertible. B) Modern view of Th
differentiation: Flexibility and plasticity of Th differentiation where differentiated
Th cells can adopt new phenotypes. From [22]. Reprinted with permission from
AAAS.
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1.5 DC subsets and T cell immunity
Differences in mDC and pDC cellular markers underlie differences in
cellular function. Although both mDCs and pDCs have functional plasticity to
elicit an appropriate immune response through T cells, it is their reaction to
specific stimuli and environment that promotes two major divergent responses T
helper 1 (Th1) and T helper 2 (Th2) immune responses, which are associated
with inflammation and allergy/antibody response, respectively. Th responses
produce specific cytokines that aid in the orchestration of appropriate defenses.
The Th1 response produces IL-2, IFN-γ, IL-12, and tumor necrosis factor (TNF)
cytokines and the Th 2 response produces IL-4, IL-5, IL-10, and transforming
growth factor (TGF-β) cytokines. At the cellular level, Th1 responses are mainly
associated with cytotoxic T lymphocytes whereas Th2 responses are associated
with induction of eosinophils and B cells. Since DCs conduct T cell responses,
pDCs can elicit a Th2 response whereas mDCs favor a Th1 response [23].
When activated by CD40 ligand (CD40L), monocyte-derived mDCs induce Th1
development with IFN-γ and IL-12 production. However, when pDCs are
activated by CD40L, they produce lower amounts of IL-12 and induce Th2
development. [24,25] (Figure 1.5).
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Figure 1.5. Human DC subsets induce different CD4+ T cell responses
based on environment and stimuli. A) Monocytes in innate immunity respond
to bacterial components through Toll-like receptor (TLRs) and secrete proinflammatory cytokines, TNF-α and IL-6. Subsequently, monocyte-derived DCs
induced by GM-CSF and IL-4 can induce a Th1 response against microbes. In
contrast, moncyte-derived DCs stimulated by mast cells and PGE2 can induce a
Th2 response. B) In response to bacterial and viral components through TLRs,
myeloid DCs (mDCs) secrete IL-12 and induce a Th1 response. However, when
stimulated with Thymic stromal lymphoprotein (TSLP), mDCs can induce a Th2
response by OX40-OX40L interaction. C) Plasmacytoid DCs (pDCs) produce
15

IFN-α in response to viral components sensed through TLR7 and TLR9. pDCs
stimulated with viruses induce cytotoxic regulatory T cells that secrete IL-10,
whereas pDCs stimulated with IL-3 induce a Th2 response through OX40OX40L ligation. ICOS ligand on pDCs induces IL-10 producing T cells, which are
important in immunoregulation. From [8]. Reprinted with permission from
Japanese Society of Allergology-Allergology International.
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1.6 Regulatory T cells
Regulatory T cells (T-regs) are a subset of CD4+ T helper cells that have
immunosuppressive and immunoregulatory capabilities and are anergic or lack
proliferative response upon T cell receptor activation. Discovered in 1969 in
mice thymectomy experiments, the thymus-derived cell subset termed
“suppressor cells” were found to be important in self-tolerance and preventing
autoimmunity [26-28]. In 1995, suppressor cells were rediscovered and termed
regulatory T cells. These suppressive T-regs were phenotypically characterized
as CD4+ T cells expressing CD25 (IL-2Rα) in mice [26,29]. However, there were
caveats to the use of CD25 as a unique marker for T-regs. CD25 is also
expressed on activated T cells and its expression is very dynamic. The
CD4+CD25+ T cell population seems to be heterogeneous with a portion of cells
exerting suppressive function, such as CD4+CD25high T cells. However, in mice,
CD4+CD25- T cells also had suppressive function. Subsequently, in 2000 and
2001, suppressive Foxp3 and CD25high expressing CD4+ T cells were found to be
associated with suppressive T-regs in humans [30,31]. Although the spectrum of
regulatory T cells includes multiple different T cell subsets, this dissertation will
focus on Foxp3+ T –regs.
Foxp3 is a forkhead transcription factor vital to the development and
function of human regulatory T cells (T-regs). Foxp3 is vital because when
mutated, there was a lack of suppressive T-regs and resulted in fatal multiorgan
autoimmune disease in mice (Scurfy) and humans (Polyendocrinopathy,
Enteropthy, X linked syndrome (IPEX)) [32-34]. When Foxp3 was ectopically
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expressed in CD4+ non-T-regs cells, suppressor function was conferred in vitro
and in vivo. Thus, Foxp3 may be an exclusive marker for CD4+ regulatory T
cells.
T-regs comprise of 5-10% of total peripheral blood mononuclear cells.
They functionally regulate a wide variety of immune cells such as CD4+, CD8+,
natural killer, natural killer T cells, B cells, and antigen-presenting cells both in
vitro and in vivo [35]. The unique capabilities of T-regs to regulate immune
reactions allow them to prevent immune diseases such as autoimmunity and
allergy. They also play a role in allograft tolerance as well as fetal-maternal
tolerance during pregnancy. In addition to their normal regulatory function, Tregs can also impede anti-tumor responses to favor tumor progression. Many
failures of cancer vaccines have been attributed to T-regs. However, T-regs also
have potential use in clinical applications for dysregulated immunity. Cellular
therapy involving in vivo expansion of T-reg in patients with autoimmune disease
would be ideal for treatment. Likewise, strategies to remove T-regs may be
helpful in augmenting a cytotoxic response to tumor antigens.
1.7 Cytotoxic T lymphocytes
Cytotoxic T lymphocytes (CTL) confer immunity against viruses and
cancer. Discovered in 1968, cytotoxic T lymphocytes’ specific cell mediated
destruction function allows for eradication of unwanted cells while leaving
bystander cells intact [36]. Because of their ability to specifically target antigens
on cells, they have been of immunologic interest for anti-tumor immunity and role
in vaccination responses to prevent infectious diseases.
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Their cytotoxic function to specifically kill target cells relies on the
molecules present on the CTL cell surface and within the cytolytic synapse
formed with target cells. CTLs express the CD8+ molecule with the T cell
receptor. In the cytolytic synapse, the molecules form a bull’s eye with the TCR in
the center. The TCR ligates with the MHC I on the target cells. At the CTL/target
cell interface, cytolytic granules (perforin and granzymes) are released to lyse
and kill the target cell [37]. Perforin, granules that perforate the cellular
membrane, are first released and then granzymes enter the cell through the
perforated membrane. To date, this is the well accepted mechanism of cytotoxic
action [38]. However, much of the protein machinery used has yet to be
identified and the cytotoxic process has yet to be completely elucidated.
Cytotoxic T lymphocytes can be idenfied by expression of cell surface
CD8, CD69 marker and IFN-γ cytokine secretion. CD69, a transmembrane Ctype lectin protein receptor involved in lymphocyte proliferation and transmission
of external signals to the inside, is expressed when CD8+ T lymphocytes are
activated through docking of CD8 + TCR on target cell MHC class I + peptide
[39,40]. CD69 activation along with cytotoxic function produces interferongamma (IFN-γ). IFN-γ is a type II IFN cytokine that signals through the JAKSTAT pathway and helps to promote an adaptive immune response against
bacteria/viruses and tumors. It is secreted in CD8+ T cells that have cytotoxic
function [41,42], [43]. Thus, a current method of identifying CTL by flow
cytometry is by intracellular expression of IFN-γ along with CD3, CD8, and CD69
markers [44-46].
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1.8 Cutaneous T cell Lymphoma (CTCL): Immunopathogenesis
Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of nonHodgkin’s peripheral T cell lymphomas that mainly impair skin. Mycosis
Fungoides (MF) and Sézary Sydrome (SS) are the most common CTCLs. They
are characterized by clonal skin-homing memory CD4+ T cells and impaired
immunity. Together they comprise of about 70% of CTCL cases and affect 6.4
per million persons. Approximately 1,500 new cases of MF/SS are reported
every year and about 16,000-20,000 persons are found alive with MF/SS in the
United States [47]. For the most part, CTCLs are incurable and thought to arise
from uncontrolled proliferation and accumulation of atypical mature helper,
memory clonal T lymphocytes [48-50]. Some patients with advanced MF and
those with Sezary Syndrome defined as erythroderma and > 1000/μL atypical
circulating malignant T cells in blood are called leukemic L-CTCL (L-CTCL)
1.9 Sézary Syndrome (SS): History and Clinical Presentation
First described by Albert Sézary in 1938, SS is a leukemia comprised of
circulating cells with cerebriform nuclei, skin erythroderma, pruritus, and
adenopathy. Patients with SS have the worst prognosis amongst all CTCL
patients with a median overall survival (OS) of only 3 years [51]. Amongst the
SS patients, we found that ≥10,000 Sézary cells/L is associated with the poorest
prognosis with a median OS of 2.4 years whereas other patients have a median
OS of >5 years [52]. SS patients typically expire from secondary and/or
nosocomial infections, most often from Staphylococcus aureus (Staph) sepsis
due to an impaired immune system, breaks in the integument and use of
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catheters. SS patients have a high rate of Staph colonization. Staphylococci
secrete erythro-toxins that cause erythroderma of skin when present in
fentamolar concentrations. Exfoliative erythroderma is defined as pink or red
skin over 80% of the body. It may be accompanied by pruritus, scaling,
infiltration, keratoderma and ectropism. Due to the bright red color exhibited
diffusely on the skin, SS has been nicknamed as the “red man syndrome”
although erythroderma may also be seen with atopic dermatitis, psoriasis, PRP,
and other skin diseases. The cause of SS is unknown but can be mimicked as
exfoliative dermatitis, making diagnosis difficult.
SS was first thought to arise from MF and may do so in a subset of
patients. Recent studies suggest that MF and SS can be separated based on
the presence of distinct T cell subsets. MF cells are effector memory T cells
whereas SS cells are central memory T cells [53]. Found both in the blood and
skin, Sèzary cells are also currently recognized as CD4+ T cells lacking CD26 or
CD7 expression [54,55]. Clonal tumor T cell populations are sometimes
identifiable by TCR Vβ clonality studies although some patients have a high
percentages of cells that are not detected by the currently available antibodies
[55].
1.10 CTCL skin and clinical pathology
Mycosis fungoides most often presents with patches or plaques while
tumors appear later in the course. All three types of skin lesions contain skin
homing epidermotropic CD4+ helper memory T cells. SS, the leukemic variant,
presents with exfoliative erythroderma (red scaly skin over > 80% of the body)
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and >1000 circulating atypical CD4+CD26- T cells, with common bone marrow
and lymph node involvement [49,50]. SS can arise de novo or evolve from preexisting MF [56]. CD8+ and CD4, CD8 double negative variants have also been
described. Although SS cells are slow growing malignant cells and are
characteristically anergic, accumulation of these tumor cells in the skin disrupts
normal immune barrier function. In addition to skin involvement, the presence of
tumor cells in blood, bone marrow, and lymph nodes is associated with worse
outcomes [57]
MF typically begins as patches or plaques similar in clinical appearance to
eczema or psoriasis. Because early MF is a chronic eczematous dermatitis, a
definitive biopsy is often delayed. Breaks in the skin barrier found as a feature of
eczema which may be due to a negative mutation in Filaggrin can induce release
of cytokines, epidermal proliferation and attraction of inflammatory T cells. In
early MF, an infiltrate of atypical lymphocytes with hyperchromatic, convoluted,
cerebrifom nuclei are found around vessels in the dermis. Epidermatropism is a
key feature required for the diagnosis of MF—either as single cells along the
dermis-epidermal junction or as collections of cells known as Pautrier’s
microabscesses composed as clusters of T cells surrounding Langerhan cells.
However, in contrast, de novo SS patients’ biopsies contain perivascular rather
than epidermotorpic atypical lymphocytic infiltrates and the diagnosis is often
missed or delayed [58].
1.11 CTCL tumor T cell abnormalities (Immunophenotype)
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Abnormal T lymphocytes found in CTCL lesions are aberrant in
development, cell migration, cell survival, cell proliferation, and apoptosis.
Although malignant cells are memory CD4+CD45RO+ T helper cells in both MF
and SS, recent studies classified MF as an outgrowth of effector memory T cells
whereas SS are central memory T cells [53,59]. In addition to this distinction,
cellular markers also differentiate MF and SS. Compared to SS cells, MF cells
are more localized to the skin. In MF cell lines, the level of skin-homing
chemokine receptor, CCR4, expression is much higher than in SS cell lines
suggesting that MF cells are more localized to the epidermis [60]. Additionally,
SS cells have a different phenotype from MF. SS cells are currently identified as
CD4+CD26- and sometimes CD4+CD7- and expansion of a specific TCR Vβ
clone. CXCL13, a chemokine found to be high in SS cells, induces not only skin
but lymph node homing properties when combined with CCR7 agonists
expressed in the lymph nodes, CCL19 and CCL21 [61].
1.12 Impaired immunity in CTCL
Normal immunity with T cell diversity allows protection from various
antigens. The variations of T cells are created by the T cell receptor (TCR)
rearrangements at the genomic level and expression on the surface of T cells.
Unique TCR are created by deletions in genomic DNA capable of recognizing
foreign antigens presented on MHC. In L-CTCL, single clones predominate and
the normal T cell repertoire is lost. These clones can be detected by flow
cytometry and PCR amplification of TCRVβ or Vγ genes. Decrease of T-cell
receptor excision circles during early T cell development in association with loss
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of T cell repertoire complexity through CDR3 spectratyping contribute to
development of clones [59,62]. The diversity of T cell repertoire was recovered
when patients were successful treated [63].
Due to the loss of T cell variety in L-CTCL patients, CD8+ T cells are
abnormally low and consequently hypothesized that the numbers of cytotoxic T
lymphocytes are also low due to depressed cell-mediated cytotoxicity marked by
Th2 dominance with eosinophilia and elevated serum IgE and IgA [64-66]. This
imbalance also reduces the activity of natural killer cells.
Since CD4+ T cells are directed by DC or antigen presenting cells through
TCR:MHC II antigen presentation, it has been reported that DC are ‘helping
hands’ in L-CTCL progression [67]. The two main DC subsets in humans,
Lineage 1 -HLA-DR+CD11c+myeloid DCs and Lineage 1-HLADR+CD123+plasmacytoid DCs, were found to be defective in numbers and
function in SS patients [68]. The failure of DCs to elicit normal responses and
prevent tumor cell outgrowth suggest an immunopathogenic role of DC.
Stimulaton of malignant L-CTCL cells with immature dendritic cells loaded with
apoptotic-T-cells in vitro exhibited a T-reg like phenotype [69]. Not only did this
study provide evidence of DC eliciting L-CTCL outgrowth, but it also suggests
that L-CTCL is an outgrowth of T-regs. However, conflicting studies show a lack
of Foxp3 expression and suppressive function in skin and blood of L-CTCL
patients, suggesting that L-CTCL is not a malignancy of T-regs, but normal Tregs may be a favorable prognostic factor [70-72]. Of interest, a recent study by
Heid et al reported findings of a subgroup of L-CTCL patients with malignant cells
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that were functionally suppressive and were CD4+Foxp3+CD25-T cells [73].
Taken together, these studies reveal the controversy over whether L-CTCL
malignant cells are T-regs or not. Thus, the role of T-regs in L-CTCL remains
unclear.
1.13 SS and current treatments
Since SS affects the skin as well as the blood, palliative topical treatment
agents are used but are ineffective for anything except symptom control.
Immunomodulatory and biological response modifiers that increase Th1 immunity
such as IFN-alpha or oral retinoids, or fusion proteins are first line therapy
combined with extracorporeal photopheresis (ECP). Second line therapies
include histone deacetylases (HDAC) inhibitors, and experimental monoclonal
antibodies directed to tumor cells (Table 1). Our recent studies have shown that
Syndecan-4, a heparin sulfate proteoglycan, expressed on activated T cells can
be depleted with dendritic cell-associated heparan sulfate proteoglycandependent integrin ligand (DC-HIL) conjugated with saporin (a toxin) suggesting
a novel opportunity to treat T cell mediated diseases [74].
Effective treatment options to reduce tumor burden and regain normal Tcell function are limited to ECP and biological response modifiers (BRM) while
other available therapies are immunosuppressive [75]. Treatment induced
immunosuppression coupled with disease-related immunosuppression means
that these patients frequently succumb to opportunistic infections especially
Staph aureus. Although a possible curative therapy for SS is non-ablative
allogeneic human stem cell transplantation (HSCT), it is feasible for only a subset
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of younger healthy patients and may cause mortality from infection, disease
reoccurrence, and chronic graft-versus-host disease (cGVHD) [76]. Treatment of
GVHD requires major immunosuppressive therapy which can lead to
opportunistic infections. Therapy with extracorporeal photopheresis (ECP) is
effective with minimal toxicity and favorably modulates immunity. Due to its
beneficial immunomodulatory effects, the mechanism of ECP action in vivo is
under investigation.
1.14 Graft versus Host disease: Immunopathogenesis
Graft versus host disease (GVHD) is an immunologic disorder that limits
wide use of allogeneic stem cell/bone marrow transplant therapy. The donor
immune cells in the transplant recognize host cells as being foreign based on
HLA mismatch. The donor cells mount an immunological attack resulting in
damage to organs including the skin, gut, liver, eyes, or lung.
In 1966, Billingham established 3 criteria necessary for GVHD: 1)
Transplanted graft has immunologically competent cells. 2) The host/recipient is
histoincompatible or has antigens that are lacking from the transplant so that the
host appears foreign. 3) The host/recipient is immunologically innocuous or
immunocompromised [77]. Two types of GVHD are characterized by
occurrence based on time after transplant. Acute GVHD is defined as occurring
within 100 days post-transplant and chronic GVHD is defined as disease that
occurs after 100 days post-transplant. In acute GVHD, a retrospective analysis
revealed that 81% patients had skin involvement, 54% had gastrointestinal (GI)
involvement, and 50% had liver involvement [78].
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According to Ferrara et al, GVHD is considered as a three-step process:
1) tissue damage to the recipient by pre-existing infections and/or
radiation/chemotherapy pre-transplant conditioning regimen and antigen
presenting cell activation; 2) T cell activation and clonal expansion of donor T
cells; and 3) cellular and inflammatory factors [79]. Prior to the infusion of donor
cells, the patient’s tissues have already been damaged by a host of factors such
as underlying disease and its treatment, infection, and the condition regimen
involving drugs and radiation. This damage activates host antigen presenting
cells (APCs) that are vital in activating donor T cells. High intensity
chemoradiotherapy also activates APCs. Inflammatory cytokines such as TNFalpha and IL-1 are secreted from host tissues as a result of total body irradiation.
Subsequently, they induce endothelial apoptosis leading to epithelial cell damage
in the GI tract. GI damage may amplify severity of GVHD if microbial products
invade the systemic circulation. These inflammatory and microbial products such
as lipopolysaccharide (LPS) are mediators of an immune response or tolerance.
They are immune ‘danger signals’ [80]. APCs activated by these danger signals
can steer the immune response towards activation or tolerance [81].
At the molecular and cellular level, major histocompatibililty complex
(MHC), CD4+ and CD8+ T cells, and cytokines are the main disease mediators.
The MHC is vital in the recognition of foreign antigens that invade the immune
system as it is unique to each individual. MHC encodes heterogenous protein
chains that present antigen to T cells through the T cell receptor and
communicates in an autologous or matched setting. The TCR: MHC interaction
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directs the T cells activity by activating or inactivating it. In the case of GVHD,
graft T cells that fail to recognize the MHC proteins on host cells mount an
immunologic attack against the host cells. Since the host is seen as foreign due
to MHC mismatch, the graft T cells attack the host cells. However, if there is a
match at the MHC loci, GVHD can also occur due to incompatibility of minor
histocompatible antigens. Since CD4+ and CD8+ T cells are matched by MHC II
and MHC I, respectively, they elicit a T cell attack due to the lack of self
recognition (Table 1.1). T cells are previously educated in the thymus to
recognize self and delete autoreactive cells in a process termed “negative
selection” [82]. Thus, the MHC and minor histocompatible antigen mismatch
attributes to the disrupted normal immunity leading to GVHD.
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Table 1.1. Comparison of L-CTCL and GVHD disease characteristics and
treatment options.

L-CTCL-Sézary

GVHD

Clinical Manifestations

Skin-Erythroderma, pruritus

Skin-Scleroderma

Disease mediated cell type

CD4+ T cells: CD4+CD26-

CD4+ T cells

Low CD8+ T cells

CD8+ T cells

Th2 dominant: IL-4, IL-5,

Th1 dominant: IL-2, IL-12,

Decreased IL-2 and IFN-γ

TNF-α, IFN-γ

Treatment strategy and

IMMUNOMODULATORY:

IMMUNOSUPPRESSIVE:

options

Extracorporeal photopheresis

Extracorporeal

plus interferon-γ,α,

photopheresis,

bexarotene, Denileukin

Glucocorticoids ,

Difitox, retinoids, steroids,

cyclosporine, tacrolimus,

Stem cell transplant - allo

rituximab

Cytokines

IMMUNOSUPRESSIVE:
campath, chemotherapy,
targeted antibodies, HDAC
inhibitors.
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1.15. Extracorporeal Photopheresis (ECP): History and Procedure
Initially developed in 1987 for the treatment of patients with high numbers
of circulating SS cells and with erythrodermic L-CTCL, ECP is extremely welltolerated with minimal side effects, improves patients' quality of life, and
increases overall survival [83]. ECP was first approved by the FDA in 1987 for
the treatment of erythrodermic L-CTCL based on a multicenter clinical trial by
Edelson et al. Response rates between 54% and 66% have been reported in LCTCL patients with about 10% complete responders [84,85]. In the ECP
procedure, 5x109 white blood cells (5-10% of PBMCs) are removed by
leukopheresis, sensitized ex vivo with a plant-derived psoralen drug, 8methoxypsoralen (8-MOP), and irradiated with 1.5 J/cm2 ultraviolet (UVA) light.
The cells are re-infused back into the hosts’ circulation (Figure 1.6). Not only is
ECP used to treat SS, but it is also effectively used to treat diseases of an
inflammatory/autoimmune etiology such as scleroderma, scleromyxedema,
fibrosing nephrogenic dermatopathy, organ transplant rejection, and
inflammatory bowel disease, etc [86-90]. How ECP can favorably treat a disease
of malignant T-cells with a possible over-abundance of T-regs and a Th2
phenotype as well as GVHD with a lack of T-regs and a Th1 phenotype is not yet
understood.
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Figure 1.6. Schematic view of ECP procedure. Reprinted with
permission from Therakos.
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1.16. ECP: Apoptosis
SS tumor cells have aberrant apoptotic pathways including decreased
Fas/Fas L and c-myc expression [91]. These defects in cell death or apoptosis
are hypothesized to contribute to the accumulation and imbalance of tumor T
cells within the blood and skin.
Following ECP, the radiated tumor cells undergo apoptosis at 24 hours
after treatment [92]. How apoptosis and cell cycle arrest occurs is in part
attributed to the DNA damage caused by covalently crosslinking thymidine bases
in lymphoma cells elicited by the 8-MOP and UVA light [93-96].
Apoptosis is a programmed cell death process and apoptotic cells induced
by ECP have effects on the patients’ immune system. Apoptotic cells following
ECP are sensed by the immune system by phagocytic dendritic cells. These
“professional antigen presenting” cells control immune responses by sampling
the environment. Following the uptake of apoptotic cells, DCs can promote an
immunologically innocuous and/or tolerizing effect. However, in some instances,
apoptotic cells provide an attractive immunogenic antigen source to DCs for
cross-priming cytotoxic T lymphocytes. Since only a small portion of the total
tumor lymphocytes are treated by ECP and prolonged clinical responses can be
observed, ECP is hypothesized to induce beneficial immunomodulating effects in
vivo. What occurs after the apoptotic cells are re-infused into SS and GVHD
patients and how it affects the patients' immune system in vivo are largely
unknown and is the subject of this dissertation.
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1.17 Immunomodulation by ECP: Vaccination Theory vs. Tolerance
The classic hypothesis of how ECP works upon re-infusion of photodamaged PBMCs into the host’s circulation is the ‘vaccination’ theory [97]. Part
of the ECP procedure circulates psoralen-treated white blood cells within a
plastic chamber during UVA irradiation leading to photoactivation of 8-MOP.
Upon photoactivation, 8-MOP intercalates into the DNA of tumor lymphocytes
and induces apoptosis. Monocytes, however, are suggested to differentiate into
dendritic cells and become more receptive to the uptake and processing of
apoptotic cells within the plastic chamber. Studies prolonging interactions with
DCs and apoptotic tumor cells by overnight incubation called “transimmunization”
have shown to be therapeutically effective when reinfused into the patient the
next day [98,99]. Transimmunization suggests that a therapeutically significant
immunobiologic modifying response orchestrated by DCs is capable by ECP to
specifically target tumors cells supports the vaccination theory of ECP
mechanism of action after re-infusion. As these apoptotic tumor lymphocytes are
a source of tumor antigen, re-infusion of tumor-antigen loaded DCs is
hypothesized to induce a vaccination response [67,98,100]. Mature dendritic
cells facilitate in vivo CD8+ T-cell maturation into cytotoxic T cells that elicit a
tumor specific attack on SS tumor cells while preserving non-pathogenic cells
[67,98,101]. Thus, DC subsets may provide evidence of ECP response. The two
DC subsets myeloid (mDC) and plasmacytoid DCs (pDC) in normal humans
have been found to induce Th1 and Th2 responses, respectively [23]. In SS
patients, DC subsets have been found to be depressed compared to healthy
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controls [68]. Efforts to increase DCs would be logical for therapy and increase
of a specific DC subset may be indicative of the in vivo T cell response.
Since CD8+ T-cells are dramatically reduced in many patients with SS and
low CD8 numbers are associated with poor prognosis and poor response to
ECP, strategies to increase their numbers may be helpful in treating SS. ECP
treated patients with close to normal levels of CD8+ T cells are observed to
respond better [102,103]. Modulation of the immune system by ECP appears to
restore the production of Th1 cytokines and may allow monocytes to become
effective tumor-antigen presenting cells to induce cytotoxic responses against
tumor T cells [104-107] . Additionally, these Th1 cytokines may promote
“normal” immunity in SS patients required for cellular immunity, and defense
against opportunistic infections [108].
However, in GVHD patients, the vaccination theory is illogical. Increase of
CD8+ T cells and Th1 cytokines would exacerbate GVHD. A previous report
showed that in GVHD, treatment with ECP is associated with a shift from
predominantly a Th1 (IL-2, INF-γ) to a Th2 (IL-4, IL-10) immune response [109],
suggesting that ECP is down-regulating Th1 immunity. Thus, it is proposed that
ECP works by immunosuppression. When apoptotic cells are endocytosed by
DCs, DCs may elicit CD4+ regulatory T cells (T-regs). A recent study reported
CD4+25high T cells, or T-regs increased in GVHD patients but decreased in LCTCL patients after six months of ECP [110]. These findings suggest that
immunosuppression through T-regs occurs in GVHD patients but not in L-CTCL
patients and favors the immunostimulatory or vaccination hypothesis in L-CTCL
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patients. In addition to GVHD, other Th1-mediated conditions such as
transplantation and autoimmune disorders benefit with immunosuppression of
inflammatory responses. In these disorders, immunotolerant DCs are generated
through the uptake of apoptotic cells and induce T-regs, cells that suppress
immunity [111]. One previous study on the effect of ECP in the GVHD murine
model reported that increased T-regs improved disease [112]. Other studies in
transplantation show that T-regs are induced after ECP and prevent GVHD and
suppress autoimmunity [113-115]. Thus, it is currently well accepted that T-regs
suppress the pathogenic cells in Th1 mediated diseases, but what specific types
of DCs or where the T-regs originate are unclear. Further validation of the
mechanism of ECP in L-CTCL and GVHD patients is needed and could provide
information for better treatment. It is hypothesized that the mechanism of ECP
action in GVHD is through immunotolerance and induction of regulatory T cells
while immunostimulation and induction of cytotoxic T lymphocytes occur in LCTCL.

1.18 Dissertation Objective and Hypothesis
The overall objective of this investigation is to elucidate the immunological
mechanisms of ECP and determine whether they are similar or different in LCTCL and GVHD patients. Regulatory T lymphocytes, Cytotoxic CD8+ T
lymphocytes, and Dendritic cell subsets from peripheral blood in L-CTCL versus
GVHD patients will be examined. Studies will be associated with clinical
response to ECP and the mechanism will be compared between the two patient
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populations. To execute this objective, I utilized peripheral blood mononuclear
cells (PBMC) isolated from peripheral blood samples taken from L-CTCL and
GVHD patients pre- and post-ECP at Day 2, 1 month, 3 months, and 6 months,
whenever possible. The central hypothesis is that ECP works differently in
L-CTCL and GVHD and that cyotoxic CD8+ T lymphocytes will be induced in
L-CTCL whereas in GVHD T-regs will be induced. My specific aims were: 1)
To determine the prevalence of functional CD4+CD25high/+Foxp3+ regulatory Tcells (T-regs) in clinically responsive L-CTCL patients after ECP treatment. 2) To
determine the prevalence of functional CD8+ cytotoxic 'killer' T-cells in clinically
responsive L-CTCL and GVHD patients after ECP treatment. 3) To characterize
the dendritic cell (DC) subsets in L-CTCL and GVHD patients on ECP and
determine a correlation in ECP-responsive patients. The general rationale of this
study is to identify the immune cell subsets that are efficacious in treating LCTCL or GVHD or that are associated with the immunological mechanism of
ECP in L-CTCL versus GVHD patients ex vivo. The significance of this study is
to better understand how ECP works immunologically to improve treatment of
patients.

I tested this hypothesis and accomplished the proposed objective by addressing
the aforementioned specific aims.

Specific Aim 1: I determined the prevalence of regulatory T cells in L-CTCL
patients and GVHD patients before and after treatment. Percentages of
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CD4+Foxp3+ were high in 7/9 L-CTCL (L-CTCL-High) patients and in 5/7 GVHD
(GVHD-High) patients studied. In 6/7 L-CTCL-High patients, percentages of
CD4+Foxp3+ T cells correlated with percentages of malignant CD4+CD26- T cells
suggesting that these malignant T cells have the T-reg phenotype. Thus, it was
determined there were 6 L-CTCL patients had the malignant T-reg phenotype
and 3 L-CTCL patients did not have a malignant T-reg phenotype. After 3
months of ECP, the L-CTCL patients with a malignant T-reg phenotype had
decreased CD4+CD26- tumor T cells and CD4+Foxp3+, CD4+Foxp3+CD25-, and
CD4+Foxp3+CD25+ T cells whereas the non-malignant T-reg phenotype patients
had no change. In the GVHD patients, there was a decrease of CD4+Foxp3+ and
CD4+Foxp3+CD25- T cells, and increase of CD4+Foxp3+CD25+ T cells after 3
months of treatment.

Specific Aim 2: I confirmed the low levels of CD8+ T cells in 6 L-CTCL patients
but high levels of CD8+ T cells in 3 GVHD patients before ECP. After ECP, the
CD3+CD8+, CD8+CD69+, CD8+IFN-y+ T cells increased after 1 month in L-CTCL
patients, but decreased in GVHD patients.

Specific Aim 3: I confirmed that DCs were low in L-CTCL and GVHD patients
before treatment. Numbers and percentages of mDCs and pDCs increased in LCTCL and GVHD patients after ECP treatment. CSSMs increased on mDCs and
pDCs. In L-CTCL patients, numbers and percentages of activated mDCs were
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increased within some responders. However, in GVHD patients, there were
increased numbers and percentages of pDCs.
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CHAPTER 2
EFFICACIES OF EXTRACORPOREAL PHOTOPHERESIS IN
PATIENTS WITH L-CTCL AND GVHD IN THIS STUDY
2.1 Background and Rationale
ECP is extremely well-tolerated with minimal side effects, improves patients’
quality of life, and increases overall survival [83]. In CTCL patients, the overall
response rate is between 54% and 66% with a 14%-33.3% complete response
rate [85,116]. In GVHD patients, 76% of patients had improved skin
manifestations with 38% complete responses [117].
To achieve more complete responses, biological response modifiers
(BRM) are administered with ECP in L-CTCL patients. Since ECP+BRM affect
the immune system, its immunologic mechanism(s) of action in vivo is of interest
and is not fully understood in L-CTCL patients.
L-CTCL patients have both blood and skin symptoms. Malignant cells,
CD4+CD26- T cells, are circulating in blood impairing immunity and the skin is
erythrodermic. Laboratory studies to enumerate these clinical presentations are
used. By flow cytometry, absolute numbers and percentages of CD4+CD26- T
cells can be measured in blood samples at baseline and following ECP therapy.
Skin involvement is calculated using a modified severity weighted assessment
tool (mSWAT) score that measures the extent and severity of skin involved in
patch, plaque, and tumor. In this study, these two parameters, numbers of
CD4+CD26- T cells and mSWAT score, were used to clinically assess disease
progression or regression. Therefore, during ECP therapy both blood and skin
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improvements were assessed by one physician (M. Duvic) in L-CTCL patients.
Skin response was defined as a > 50% decrease in the mSWAT score at
baseline. Response in the blood was subsets or the TCR Vβ clone, where
available.
2.2 Patients and Methods
Please see Chapter 7.
2.3 Results
Eighteen L-CTCL patients completed the 6-month treatment course. Their
individual characteristics and responses are shown in Table 2.1. Demographics
and response rate are summarized in Table 2.2. The cohort consisted of more
Caucasians (16/18, 88.9%) and males (13/18, 72.2%) with a median age of 67.0
(54-79) years. All patients had ≥ 39.0 mSWAT except pt. # 17 who had normal
skin (mSWAT 5.0). Confluent erythema (≥ 87.0 mSWAT) was observed in 7
patients who met the criteria for SS. According to the revised criteria for MF/SS
staging by ISCL/EORTC, 16/ 18 patients were diagnosed with MF/SS stage IV
(8-SS IVA and 8-SS IVB) and 2 were staged as MF/SS IIIB. Patient #8 had
MF/SS stage IIIB in addition to chronic GVHD. With the exception of patient #4
(20.6%), all patients had ≥ 50% circulating CD4+CD26- tumor T cells. Fifteen of
18 patients (83.3%) had B2 (High tumor burden, >1000/μL CD4+ CD26- T cells)
and 3/18 (16.7%) had B1 (Low tumor burden, <1000/μL CD4+CD26- T cells). In
16/18 patients, dominant TCRvβ clones were identified.
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All L-CTCL patients were previously treated with skin directed therapies,
but none were treated with radiation, chemotherapy, or immunosuppressive
agents.
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Table 2.1. Clinical summary of L-CTCL patients on extracorporeal
photopheresis
Pt.#
1
2

Age/Gender/Race
58/F/C

66/M/C

3

71/M/AA

5

74/F/C

4

54/M/C

6

74/M/C

7

67/M/C

9

66/F/C

8**

61/M/C

10

74/M/C

12*

71/M/C

11

79/M/C

Stage
SS IVA

ECP
Cycles

TCR
vβ%
Vβ
(70.0)
Vβ22
(91.0)
None

SS/MF
IIIB
SS IVB
(HTLV+)
MF IVA

10
7

Bexarotene
IFN-α
Bexarotene
IFN- α
Bexarotene
IFN- α
None

MF/SS
IVB
(BM+)
SS IVA

7

None

SS IVB

GVHD,
MF/SS
IIIB
SS IVB
SS/MF
IVA
SS IVB
(BM+)

7

Additional
Therapy

7

11

Bexarotene

12

Bexarotene

13

Bexarotene
IFN-α
None
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11
9

IFN-α

Bexarotene

SS/MF
IVA
SS IVB

10
10

Bexarotene
IFN-α
None
IFN-α

13

78/F/AA

14

63/M/C
73/M/C

SS IVB
(BM+)
SS IVA

10
10

Bexarotene

16

67/F/C

SS IVA

6

Bexarotene

61/M/C

SS IVB

8

None

15
17***
18

63/M/C

SS IVA

6

None

Vβ17
(54.0)
Vβ
(85.0)
Vβ8
(73.7)
Vβ
(83.0)
Vβ
(76.0)
Vβ2
(97.0)
Vβ7.2
(93.0)
Vβ
13.6
(97.1)
Vβ 17
(94.0)
Vβ
13.6
(95.0)
Vβ
(94.0)
Vβ
18.0
(95.0)
n/d
Vβ
5.1
(95.0)
Vβ
7.1
(97.0)

Skin
mSWAT

Blood
CD4+CD26-T
cells
%
μL

63.0

64.2

1751.0

100.0

55.5

525.0

100.0
39.0
93.0

82.2
20.6

413.0
69.0

Response
Skin

Blood

Overall

PR

CR

PR

MR

SD

SD

PD

PD

PR

SD

PR
PR

SD

SD

SD

89.9

3928.0
2218.0

MR

PR

87.0

79.1

1671.0

PR
SD

SD

MR

MR

100.0

93.8

17981.0

SD

SD

SD

54.0

PR

SD

74.0
77.0

48.1

73.7
64.4

87.5

2752.0

11581.0

PR

100.0

56.0

1284.6

49.0

PR

SD

PR

9977.0

SD

PD

PD

PD

94.7

22751.0

PR

SD

PR

67.0

91.9

4300.0
5139.0

PR

MR

SD
SD

PR

MR

87.0

91.7

5500.0

MR

SD

MR

47.0
47.0
5.0

85.9

227.0

94.5
77.1
91.7

2600.0

SD

SD
SD

yrs = years, M=male, F=female, C=Caucasian, AA-African American, MR=minimal response, SD=stable disease, PR=partial
response, PD=progressive disease,TCR=T-cell receptor, pts=patients, BM=bone marrow, GVHD=Graft-versus-host disease,
SS=Sézary Syndrome, MF=Mycosis Fungoides, HTLV=Human T Lymphotrophic Virus, n/d = not done, mSWAT=modified
severity weight assessment tool, ECP=Extracorporeal photopheresis

*CD4+CD7- T cell phenotype present instead of CD4+CD26-.
** Patient with both GVHD and MF/SS who underwent the greatest number of ECP cycles (25).
***Patient with normal skin and malignant T-reg phenotype CD4+Foxp3+ (Shiue, LH et al 2012)
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MR

PR

PD
SD

Table 2.2. L-CTCL Patient demographics and response rate.

Characteristic
Gender

L-CTCL (n=18)
Male (n=13, 72.2%)
Female (n =5, 27.8%)

Median Age (range)

67 (54-79) years

Race

Caucasian (n=16, 88.9%)
African American (n=2, 11.1%)

Stage-no. of patients (%)

SS/MF IIIB-11.1%
SS/MF IVA-44.4%
SS IVB-44.4%

Tumor burden (TB)

High TB (>1000/μl) 83.3%
Low TB (<1000 /μl) 16.7%

TCRVβ+ pts (%)

88.9%

Median ECP cycles after 6
mos (Range)

9.9 (6-25)

Response - no. of pts (%)
Complete response (CR)
Partial response (PR)
Minor response (MR)
Stable disease (SD)
Progressive disease (PD)
Deceased

none
n=8 (44.4%)
n=4 (22.2)
n=3 (16.7%)
n=3 (16.7%)
none

Combination therapies

66.7%
Response
Rate

ECP alone (n=6)
ECP + Bexarotene (n=5)
ECP + IFN-α (n=2)
ECP+ Bexarotene+IFN-α (n=5)
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At recruitment, all patients were beginning ECP for the first time. Six of 18
L-CTCL patients were treated with ECP only. For lack of response, biological
response modifiers were added at 3 or more months after initial ECP. Five
received only Bexarotene at 150 or 225 mg per day, two received only interferon
alpha at a dose of 3 milllion daily or three times per week (+IFN-α), and five
received both Bexarotene and IFN-α. The average number of ECP cycles
administrated to L-CTCL patients was 9.9 over a six-month treatment period.
At the end of study or 6 months, the overall response rate to ECP was
66.7%,(12/18) with 8 patients achieving partial responses (PR, 44.4%) and 4 with
minor responses (MR, 22.2%). There were no complete responses. The nonresponse rate was 33.3% (6/18) with 3 patients having stable disease (SD,
16.7%) and 3 with progressive disease (PD, 16.7%). Responses were
determined by changes in mSWAT scores (Figure 2.1A) and/or circulating
CD4+CD26- tumor T cells (Figure 2.1B) from baseline shown for all patients.
At baseline, there were no significant differences in mSWAT between
responders and non-responders. Similarly, at baseline, there were no significant
differences in CD4+CD26- T cells between responders and non-responders.
After 6 months, there was a decrease in CD4+CD26- T cells in both responders
(Figure 2.1C) and non-responders (Figure 2.1D). The mSWAT significantly
decreased in responders (67.023.7, p=0.0004) but not in non-responders
(72.273.4, p=0.63).
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B

A

C

D

Figure 2.1
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Figure 2.1. Clinical skin (mSWAT) and blood response (CD4+CD26- T cells)
from baseline (BL) to 6 months (6M) of ECP-BRM therapy
A) Percentage change in mSWAT from baseline (BL) to 6 months (6M) in all
18 patients.
B) Percentage change in CD4+CD26- T cells/μL from baseline (BL) to 6
months (6M) in all 18 patients.
C) Skin (mSWAT, ▲) and blood (CD4+CD26- T cells/μL, ■) response at
baseline (BL), 1 month (1M), 3 months (3M), and 6 months (6M) in 12
responding patients.

D) Skin (mSWAT, ▲) and blood (CD4+CD26- T cells /μL, ■) response at BL,
1M, 3M, and 6M in 6 non-responding patients.
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Eleven GVHD patients summarized in Table 2.3 who enrolled in this study
had either a non-L-CTCL primary lymphoma or leukemia. They developed acute
and chronic GVHD after matched non-ablative stem cell transplantation. All
patients had skin involvement, and all received standard immunosuppressive
therapy for GVHD in addition to ECP. GVHD patients received an average of
14.6 to 29.9 cycles of ECP treatment in a 3 to 6-month period. After 3 to 6
months treatment, 6 of 11 (54.5%) had achieved skin and/or other organ
improvements (Table 2.4).
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Table 2.3. Clinical summary of GVHD patients on extracorporeal photopheresis
GVHD
Patient
#
1

Age/Sex/
Race

Primary Disease

Type of
Donor

Type of
GVHD

Organs affected

Concurrent
therapies

ECP cycles at
3/6 months

2

60/F/C

NHL
NHL

Skin
(sclerodermoid),
Mouth
Skin

3

Match related
sibling

De novo
chronic

29/M/C

CLL

Cord blood

Late acute

52/M/C

CML

Match related
transplant

Classic
chronic

5

Skin (nonsclerodermoid),
Gastrointestinal
Skin
(sclerodermoid),
eyes, liver, lung

Tacrolimus
Methylprednisolon
e
Steroids,
Mycophenolate,
Methylprednisolon
e
Mycophenolate,
Prednisone,
Tacrolimus
Steroids,
Erythromycin,
Prednisone

7/12

50/M/C

Match
unrelated

62/M/C

CLL

6

Match
unrelated

Classic
Chronic

Skin(sclerodermoid
), liver, ,oral, eyes

55/F/C

SLL

Classic
chronic

7

50/M/C

CLL

Match
Related
Donor-from
male donor

Match related
donor

8

23/M/C

Aplastic anemia

Match related

10

52/M/C

11

HL B cell
lymphoma

62/F/C

Myelodysplastic
syndrome /
follicular
lymphoma

4

9

55/F/C

AML

Match
related

HLA
matched
sibling
Matchsibling

Acute,
Grade 4 of
skin

Overlap
syndrome
(both
chronic &
acute)
Late acute
Classic
chronic

De novo
chronic
Overlap
syndromeboth acute &
chronic

No Response

Clinical response at 6
months
GVHD progression

Skin-Partial response

n/a

14/25

No response

Partial response

9/25

Stable disease

Tacrolimus

19/43

Skin(sclerodermoid
), joints- fascia,
mouth, liver, eye

Tacrolimus,
Methylprednisolon
e

23/37

Skin-Partial response
Liver-Complete response
Eye-no response
Mouth-partial response
Skin-Progression
Eye-Progression
Liver-normal

Eye-no response
Skin-no response
Lungs-partial response
Liver-complete response
Overall-partial response
Skin - Partial response
Liver-Complete response
Eye -no response
Mouth-partial response
Skin-minor response
fascia -Improved
Mouth-partial responses

Liver, skin-involved
but not active
Skin, fascia, liver,
Gastrointestinal
tract (acute)
skin
(sclerodermoid),
Mouth, eye, lung

Methylprednisolon
e, Tacrolimus
Prednisone,
Tacrolimus,

14/n/a
stopped ECP
11/35

No response

No response

Steroids,
Azithromycin

21/32

Stable disease ( Skin,
Eyes, Lung, Mouth)

Tacrolimus, Methyl
prednisone

23/30

Stable Disease

Skin (scleroderma),
fascia, liver, mouth

Skin
(sclerodermoid,
macular popular)
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Mycophenolate ,
Methylprednisolon
e, Imatinib,
Tacrolimus

5/n/a
stopped ECP

Clinical Response at 3
months

n/a

Skin-Partial response
Fascia-Partial response
Liver-Complete response
Mouth- Complete
response
No Response

Skin-Partial response
Fascia-Partial response
Liver-Complete response
Mouth- Complete
response
No response-progression
Stable disease (Eyes, Lung)
Partial response
(Skin, Mouth)
Stable Disease

GVHD: Graft versus Host Disease, F: Female, M: Male, C: Caucasian, ECP: Extracorporeal Photopheresis, n/a: not available, HL: Hodgkin’s Lymphoma, NHL=Non-Hodgkin’s Lymphoma,
AML: Acute myelogenous leukemia, CLL: Chronic lymphocytic leukemia, CML: Chronic myelogenous leukemia, SLL=Small Lymphocytic Lymphoma
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Table 2.4. GVHD patients’ demographics and response rate.

Characteristic
Gender

GVHD (n=11)
Male (n=7, 63.6%)
Female (n =4, 36.4%)

Median Age (range)
Race

52 (23-62) years
Caucasian (n=11, 100%)

Type of GVHD-no. of patients
(%)

Acute-9.0%
Late acute-18.2%
Denovo, chronic-18.2%
Classic Chronic-36.4%
Overlap (Acute & Chronic)-18.2%
After 3 mos: 14 (5-23)
After 6 mos: 31 (12-43)

Median ECP cycles (Range)
Response - no. of pts (%)
Complete response (CR)
Partial response (PR)
Minor response (MR)
Stable disease (SD)
Progressive disease (PD)
No Response (NR)
Response not available

none
n=4 (36.4%)
n=1 (9.0%)
n=1 (9.0%)
n=2 (18.2%)
n=2 (18.2%)
n=1

Combination therapies

54.5%
response
rate

ECP alone (n=0)
ECP + Tacrolimus (n=8)
ECP + Steroids (n=3)
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2.4 Discussion & Conclusions
Since 12 of 18 L-CTCL patients (66.7%) and 6 of 11 GVHD patients (54.5%)
achieved clinical responses with ECP, this study further confirms the efficacy of
ECP in treatment for L-CTCL and GVHD [85,116,117]. A confounding factor in
this study is that 12 of 18 L-CTCL and all GVHD patients received additional
immunomodulatory therapies initiated at 1 or 3 months after starting ECP. These
include Bexarotene and IFN-α in L-CTCL patients and steroids and Tacrolimus in
GVHD patients. We therefore cannot rule out effects of these agents on
response and the modulation on DCs, T-regs, and CTLs in these patients.
However, combined immunotherapy is widely used in both diseases, and a study
devoid of these agents is not currently possible. Of interest, 4 of 6 (66.7%) LCTCL patients who received ECP alone and 8 of 12 (66.7%) who received ECP
with immunomodulatory therapy achieved the same overall clinical response
rates, suggesting that most of the beneficial response may be attributed to ECP.

52

53

CHAPTER 3
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON REGULATORY T
CELLS IN PATIENTS WITH L-CTCL AND GVHD
3.1. Background and Rationale
Regulatory T cells (T-reg) are immunosuppressive T cells that regulate
immune reactions. The CD4+ Foxp3+CD25+ T-reg phenotype is the most
understood type, but other phenotypes exist. CD4+Foxp3+ T cells were termed
“naturally occurring” T-regs to distinguish them from in vitro generated
“suppressor cells” [118]. A recent study reported that CD4+ Foxp3+CD25- T cells
found in the periphery are reservoirs of inactive T-regs ready to activate when
necessary [119].
Because of the existence of multiple T-reg phenotypes, data on T-regs in
L-CTCL are limited and controversial. Both T-regs and L-CTCL cells share
similar characteristics. They are both CD4+ and anergic T cells. Therefore, it is
thought that the L-CTCL malignant clones may be T-regs. Whether L-CTCL
tumor cells are T-regs or not or if there is heterogeneity among L-CTCL patients
is unclear. As an expansion of anergic CD4+ T cells, MF/SS tumor cells
suppress anti-tumor immunity and secrete Th2 cytokines [69,72,73]. Heid et al
found a subset of SS patients with malignant suppressive CD4+ Foxp3+CD25- T
cells and reported that tumors may be T-regs [50]. Conversely, in other studies,
the T-reg phenotype was absent in L-CTCL [70,71,120].
ECP has been hypothesized to induce T-regs in both
autoimmune/inflammatory diseases and in Graft-versus-Host Disease (GVHD);
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however, it is unknown if T-regs are also induced by ECP in L-CTCL patients. To
address this question, we examined three Foxp3+ T cell subsets in L-CTCL and
GVHD patients before and after ECP treatment at Day 2, 1 month, 3 months, and
6 months-2 years. We investigated CD4+Foxp3+, CD4+ Foxp3+ CD25-, and CD4+
Foxp3+CD25+ T cells within peripheral blood mononuclear cells (PBMCs) by
immunofluorescence flow cytometry and Foxp3 mRNA within PBMCs by
quantitative real time PCR.
3.2 Patients and Methods
Please refer to Chapter 7
3.3 Results
Patients and clinical response
Please refer to Chapter 2
CD4+ Foxp3+ CD25- and CD4+Foxp3+CD25+ T cell subsets differ in patients
with L-CTCL and GVHD at baseline.
Percentages of CD4+Foxp3+ T cells were significantly higher than normal
(8.3±2.6%) in both L-CTCL and GVHD. Between the L-CTCL (n=9, 66.8±41.2%,
p=0.03) and GVHD (n=7, 66.2±42.0, p=0.05) patients, percentages of
CD4+Foxp3+ T cells were similar (Figure 3.1A). Although percentages of
CD4+Foxp3+ T cells were similar in L-CTCL and GVHD, percentages of CD4+
Foxp3+CD25- and CD4+ Foxp3+CD25+ T cell subsets differed between the
disease groups. Percentages of CD4+ Foxp3+CD25- T cells were higher in LCTCL (48.5±32.3%) versus GVHD (22.9±25.3%) patients (Figure 3.1B) whereas
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CD4+ Foxp3+CD25+ T cells were significantly lower in L-CTCL (17.2±18.1%,
p=0.04) versus GVHD (47.1±36.1%) patients (Figure 3.1C).
The percentages of CD4+Foxp3+ T cells within L-CTCL patients were
either higher (L-CTCL-High, 85.5±20.8%, n=7) or lower (L-CTCL-Low, 1.4±1.1%,
n=2) than normal donors (ND) (Figure 3.1D). No L-CTCL patients were within
normal range (5.7-10.9%). Within GVHD patients, percentages of CD4+Foxp3+ T
cells were significantly higher than normal in 5/7 patients (GVHD-High,
90.6±5.7%, p=4.5*107), lower than normal in 1/7 patients (GVHD-Low), and
normal in 1/7 patients (GVHD-Normal) (Figure 3.1E). Interestingly, 77.8% (7/9)
of L-CTCL patients (L-CTCL-High) and 71.4% (5/7) of GVHD patients (GVHDHigh) had significantly higher than normal percentages of CD4+Foxp3+ T cells
(Figure 3.2C).

CD4+ Foxp3+CD25- and CD4+ Foxp3+CD25+ T cell subsets differ between the
L-CTCL-High and GVHD-High patients
Since the majority of L-CTCL and GVHD patients had high percentages of
CD4+Foxp3+ T cells, we next compared the CD4+Foxp3+CD25- and
CD4+Foxp3+CD25+ T cell subsets between the L-CTCL-High and GVHD-High
patients. L-CTCL-High patients (62.1±20.5%, p= 0.03) had significantly higher
percentages of CD4+ Foxp3+CD25- T cells than GVHD-High patients
(27.4±25.4%) (Figure 3.2B,D). In contrast, percentages of CD4+ Foxp3+CD25+ T
cells were significantly lower in L-CTCL-High patients (22.1±17.7%, p=0.009)
compared to GVHD-High patients (63.6±27.5%) (Figure 3.2B, E). These data
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suggest that L-CTCL and GVHD patients may be harboring pathogenic Foxp3+
phenotype cells prior to treatment.

Malignant T cells with a Foxp3+ phenotype in 6/7 L-CTCL-High patients at
baseline
Whether the tumor cells are Foxp3+ regulatory T cells (T-regs) in at least
some L-CTCL patients is controversial. Berger et al reported that L-CTCL is a
malignancy of T-regs [69], but other studies show a lack of malignant T cells with
a Foxp3+ phenotype in majority of L-CTCL patients [70,71,73]. In our study, we
investigated 9/18 patients’ T-reg phenotypes and their correlation to malignant Tcell populations as defined by their expression of CD4+CD26- [121].
We found that patients with greater than 50% of CD4+CD26- T cells also
had greater than 50% of CD4+Foxp3+ T cells. There is a correlation between
CD4+ Foxp3+ and CD4+ Foxp3+ CD25- T cells and malignant CD4+CD26- T cells
in 6/7 L-CTCL-High patients (Figure 3.3A), but no correlation in 1 L-CTCL-High
and the 2 L-CTCL-Low patients (Figure 3.3B). As expected, the percentages of
malignant cells and CD4+Foxp3+ T cells positively correlated within L-CTCL High
patients (R=0.54) (Figure 3.3C). There was also a positive correlation between
percentages of malignant cells and CD4+Foxp3+CD25- T cells (R=0.58)
suggesting that these malignant cells have a Foxp3+ phenotype but CD25
negative (Figure 3.3D). There was a negative correlation between malignant
and CD4+ Foxp3+CD25+ T cells (R=-0.34) (Figure 3.3E). All T cell percentages
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and numbers in these L-CTCL-High and L-CTCL-Low patients are summarized in
Table 3.2.
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Figure 3.1. Foxp3+ T cells in L-CTCL and GVHD patients.
A) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCL and
GVHD patients at baseline.
B) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in LCTCL and GVHD patients at baseline.
C) Dot graph displaying the percentages of CD4+ Foxp3+CD25+ T cells in LCTCL and GVHD patients at baseline.
D) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCL
patients with High (L-CTCL-High) and Low Foxp3 (L-CTCL-Low) at
baseline.
E) Dot graph displaying the percentages of CD4+Foxp3+ T cells in GVHD
patients with High (L-CTCL-High), Low (L-CTCL-Low), and Normal (LCTCL-Normal) Foxp3 at baseline.
* denotes statistical significance, p-value<0.05

60

Table 3.1. T lymphocyte parameters in normal donors (ND) versus L-CTCL
versus GVHD patients before ECP.

ND
(n=3)

L-CTCL
(n=9)

GVHD
(n=7)

CD4+Foxp3+ (μl)

9.9±7.9

3640.7±7226.2

76.0±158.9

p-value
0.22

CD4+Foxp3+ (%)

8.3±2.6

66.8±41.2*

66.2±42.0*

0.98

CD4+ Foxp3+ CD25-(μl)

3.7±4.2

3067.7±6126.9

40.3±95.9

0.22

CD4+ Foxp3+ CD25-(%)

2.6±3.5

48.5±32.3*

22.9±25.3

0.13

CD4+ Foxp3+CD25+(μl)

10.6±11.9

555.9±1079.5

36.4±65.6

0.2

CD4+ Foxp3+ CD25+(%)

7.7±2.4

17.2±18.1

47.1±36.1

0.05

CD4+CD25high (μl)

n/a

285.8±569.3

n/a

n/a

CD4+CD25high (%)

0.6±0.5

3.2±5.4

9.6±6.0

0.07

Foxp3 mRNA

0.9±0.5

27.0±48.9*

0.1±0.1

0.30

p-value between L-CTCL and GVHD
*= p<0.05 compared to normal
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Table 3.2. T lymphocyte parameters in normal donors (ND) versus L-CTCLHigh versus L-CTCL-Low patients before ECP.

ND (n=3)

L-CTCL-High (n=7)

L-CTCL-Low (n=2)

p-value

CD4+Foxp3+ (μl)

9.9±7.9

4674.2±8001.0

23.3±29.1

CD4+Foxp3+ (%)

8.3±2.6

85.5±20.8*

1.4±1.1

0.0009
0.5

CD4+ Foxp3+ CD25-(μl)

3.7±4.2

3933.7±6790.7

36.8±49.1

0.5

CD4+ Foxp3+ CD25-(%)

2.6±3.5

62.1±20.5*

0.98±0.7

0.005

CD4+ Foxp3+CD25+(μl)

10.6±11.9

714.1±1192.5

1.86±2.5

0.4

CD4+ Foxp3+CD25+(%)

7.7±2.4

22.1±17.7

0.2±0.2

0.1

CD4+CD25high (μl)

n/a

107.8±80.7

908.8±1247.3

0.07

CD4+CD25high (%)

0.6±0.5

1.7±2.2

8.5±11.6

0.1

Foxp3 mRNA

0.9±0.5

30.9±51.4

0.2

n/a

CD4 CD26 (μl)

n/a

5208.4±7933.0

6288.5±5216.3

0.8

85.8±12.3

0.5

+

-

+

-

CD4 CD26 (%)
n/a
78.4±14.8
p-value between L-CTCL High and L-CTCL Low
*= p<0.05 compared to normal
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Table 3.3. T lymphocyte parameters in normal donors (ND) versus GVHDHigh versus GVHD-Low versus GVHD-Normal patients before ECP.

GVHD-Low
(n=1)

GVHDNormal
(n=1)

p-value

ND (n=3)

GVHD-High
(n=5)

CD4+Foxp3+ (μl)

9.9±7.9

106.2±184.1

0.2

CD4+Foxp3+ (%)

8.3±2.6

90.6±5.7

92.2

0.8
10.3

0.4
7
4.5*10

CD4+ Foxp3+ CD25-(μl)

3.7±4.2

56.4±112.5

0

0.03

0.5

CD4+ Foxp3+ CD25-(%)

2.6±3.5

27.4±0.2

54.6

0.4

0.2

CD4+ Foxp3+CD25+(μl)

10.6±11.9

50.9±74.4

0

0.9

0.4

CD4+ Foxp3+CD25+(%)

7.7±2.4

63.6±27.5

38.7

12.0

0.01
n/a

CD4+CD25high (μl)

n/a

n/a

n/a

n/a

CD4+CD25high (%)

0.6±0.5

10.4±6.6

n/a

6.3

0.001

Foxp3 mRNA
0.9±0.5
p-value between GVHD High and ND

0.1±0.03

n/a

0.3

0.02
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Table 3.4. T lymphocyte parameters in normal donors (ND) versus L-CTCLHigh versus GVHD-High patients before ECP.

ND
(n=3)

L-CTCL-High
(n=7)

GVHD-High
(n=5)

CD4+Foxp3+ (μl)

9.9±7.9

4674.2±8001.0

106.2±184.1

CD4+Foxp3+ (%)

8.3±2.6

85.5±20.8*

90.6±5.7*

0.2
0.6

CD4+ Foxp3+ CD25-(μl)

3.7±4.2

3933.7±6790.7

56.4±112.5

0.2

CD4+ Foxp3+ CD25-(%)

2.6±3.5

62.1±20.5*

27.4±25.4

0.03

CD4+ Foxp3+CD25+(μl)

10.6±11.9

714.1±1192.5

50.8±74.4

0.2

p-value

CD4+ Foxp3+CD25+(%)

7.7±2.4

22.1±17.7

63.6±27.5*

0.009

CD4+CD25high (μl)

n/a

107.80.7

n/a

n/a

CD4+CD25high (%)

0.6±0.5

1.7±2.2

10.4±6.6*

0.009

0.07±0.03*

0.5

Foxp3 mRNA
0.9±0.5
30.9±51.4
p-value between L-CTCL-High and GVHD-High
*= p<0.05 compared to normal
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A

ND

L-CTCL-High
Pt. #5

GVHD-High
Pt. #6

B

*

*

*

*

Figure 3.2
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*

*

Figure 3.2. Division of patients based on baseline percentages of
CD4+Foxp3+ T cells by flow cytometry.
A) Representative flow cytometry dot plots of CD4+Foxp3+ T cells (upper
right quadrant) from a normal donor (ND, left), patient 5 (Pt. 5-CTCL-High
CD4+Foxp3+ T cells, middle), and patient 6 (Pt. 6-GVHD-High CD4+Foxp3+
T cells, right).
B) Representative flow cytometry dot plots of CD4+ Foxp3+CD25-T cells
(upper left quadrant) and CD4+ Foxp3+CD25+T cells (upper right quadrant)
from normal donor (ND, left), patient 5 (Pt. 5-CTCL-High CD4+Foxp3+ T
cells, middle), and patient 6 (Pt. 6-GVHD-High CD4+Foxp3+ T cells, right).
C) Patients were divided according to the percentages of CD4+Foxp3+ T cells
in peripheral blood. Dot plot displaying percentages of CD4+Foxp3+ T
cells in normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High
(n=5).
D) Dot graph displaying the percentages of CD4+ Foxp3+CD25-T cells in
normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High (n=5).
E) Dot graph displaying the percentages of CD4+ Foxp3+CD25+T cells in
normal donors (ND, n=3), CTCL-High (n=7), and GVHD-High (n=5).
* denotes statistical significance, p<0.05
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A

B

C

R=0.54

D

R=0.5

Figure 3.3
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E

R=-0.34

Figure 3.3. Correlation analysis of Foxp3+ T cell subsets and malignant
CD4+CD26- T cells in L-CTCL-High and L-CTCL-Low patients
A) Comparison of percentages of malignant CD4+CD26- T cells and
percentages of CD4+Foxp3+ T cells, CD4+ Foxp3+CD25- T cells, CD4+
Foxp3+CD25+T cells, and Foxp3 mRNA(from left to right) in the 6 L-CTCLHigh patients.
B) Comparison of percentages of CD4+CD26- tumor T cells and percentages
of CD4+Foxp3+ T cells, CD4+ Foxp3+CD25-T cells, CD4+ Foxp3+CD25+T
cells, and Foxp3 mRNA(from left to right) in the 2 L-CTCL-Low patients.
C) Scatter plot revealing a positive correlation between CD4+CD26- T cells
and CD4+Foxp3+ T cells in the 6 L-CTCL-High patients.
D) Scatter plot revealing a positive correlation between CD4+CD26- T cells
and CD4+ Foxp3+CD25-T cells in the 6 L-CTCL-High patients.
E) Scatter plot revealing a negative correlation between CD4+CD26- T cells
and CD4+ Foxp3+CD25+T cells in the 6 L-CTCL-High patients.
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Decrease of malignant cells with Foxp3+ T-reg phenotype after treatment
with ECP in L-CTCL patients
We next studied the effects of ECP on CD4+Foxp3+, CD4+ Foxp3+CD25-,
and CD4+Foxp3+CD25+ T cells in L-CTCL High (Table 3.5). We found a
decrease in percentages and numbers of CD4+Foxp3+ (Figure 3.3A), CD4+
Foxp3+CD25- (Figure 3.3B), and CD4+ Foxp3+CD25+ T cells (Figure 3.3C) in the
L-CTCL-High through the treatment timepoints. Six of the 7 L-CTCL-High
patients have the malignant Foxp3+ phenotype and were responders to ECP
treatment. Therefore, this data show that these malignant Foxp3+ phenotype
cells decrease with treatment suggesting that there is an association to
response.

Decrease of Foxp3+ T cells after treatment with ECP in GVHD patients
In the GVHD-High Foxp3 patients, the effects of ECP on percentages and
number of CD4+Foxp3+, CD4+ Foxp3+CD25-, and CD4+Foxp3+CD25+ T cells in
GVHD-High patients are summarized in Table 3.6. Percentages of CD4+Foxp3+
T cells remained the same after 3-4 months of treatment. However, percentages
of CD4+Foxp3+CD25- decreased while CD4+Foxp3+CD25+ T cells trended to
increase after 3-4 months of treatment (Figure 3.3D-F). There were 4/5
responders within these patients.
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Table 3.5. Percentages (mean±SD) and numbers of T lymphocytes and Foxp3 mRNA in L-CTCL-High patients
before and after ECP.

BL

D2

1M

3M-4M

6M-10M

1YR-2YR

CD4+Foxp3+ (μl)

4674.2±8001.0

3300.9±3656.9

990.3±896.1

3015.6

314.9±521.2

5.05

CD4+Foxp3+ (%)

85.5±20.8*

94.4±3.9

68.9±51.5

52.5±56.5

64.6±44.9

98.1

CD4+CD25-Foxp3+ (μl)

3933.7±6790.7

2644.4±2866.5

1177.8±499.7

4991.8

357.5±493.1

2.3

CD4+CD25-Foxp3+ (%)

62.1±20.5*

70.2±8.9

54.9±40.1

44.5±45.3

42.9±26.6

44.3

CD4+CD25+Foxp3+ (μl)

714.1±1192.5

649.1±88.3

187.3±158.7

494.5±699.2

58.1±92.9

2.8

CD4+CD25+Foxp3+ (%)

22.1±17.7

24.0±12.8

13.8±12.4

7.9±10.3

20.7±22.8

53.8

CD4+CD25high (μl)

107.8±80.7

n/a

97.1±87.8

75.0±66.3

243.6±368.5

n/a

CD4+CD25high (%)

1.7±2.2

2.1±1.9

1.1±0.6

1.2±0.7

3.4±3.9

n/a

Foxp3 mRNA (n=7)

30.9±51.4

36.0±67.0

20.8±40.8

11.3±19.5

19.2±39.9

n/a

CD4+CD26- (μl)

5208.4±7933.0

n/a

3878.3±5109.7

2318.6±2446.4

CD4+CD26- (%)
n/a: not available

78.4±14.8

n/a

72.8±20.3

69.2±26.2
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2456.3±1907.0
72.5±25.0

n/a
n/a

Table 3.6. Percentages (mean±SD) and numbers of T lymphocytes and Foxp3 mRNA in GVHD-High patients before and
after ECP.

BL

D2

1M

3M-4M

6M-10M

1YR-2YR

CD4+Foxp3+ (μl)

106.2±184.1

13.0±19.0

18

10.1±6.4

22.2

n/a

CD4+Foxp3+ (%)

90.6±5.7*

57.7±51.3

85.9

96.0±2.1

86.2

n/a

CD4+CD25-Foxp3+ (μl)

56.4±112.5

1.3±1.1

11.2

0.4±0.1

2.3

n/a

CD4+CD25-Foxp3+ (%)

53.5

4.4±2.7

8.8

n/a

27.4±25.4

3.1±2.9

CD4+CD25+Foxp3+ (μl)

50.8±74.4

12.3 ±17.9

7.4

9.7±6.3

19.9

n/a

CD4+CD25+Foxp3+ (%)

63.6±27.5*

55.1±48.8

35.2

91.9±2.4

77.4

n/a

CD4+CD25high (μl)

n/a

n/a

n/a

n/a

n/a

n/a

CD4+CD25high (%)

10.4±6.6*

15.7±14.1

8.9±8.3

10.4±4.5

n/a

n/a

Foxp3 mRNA (n=3)
n/a: not available
*

0.07±0.03*

0.05±0.02

0.05±0.02

0.05

n/a

n/a
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A

B

D

Figure 3.4

C

E

F
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Figure 3.4. Changes in numbers of Foxp3+ T cell subsets after ECP-BRM in
L-CTCL-High and GVHD-High patients by flow cytometry.
A) Dot graph displaying the percentages of CD4+Foxp3+ T cells in L-CTCLHigh patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months (34M), and 6-10 months (6-10M).
B) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in LCTCL-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months
(3-4M), and 6-10 months (6-10M).
C) Dot graph displaying the percentages of CD4+ Foxp3+CD25+ T cells in LCTCL-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months
(3-4M), and 6-10 months (6-10M).
D) Dot graph displaying the percentages of CD4+Foxp3+ T cells in GVHD-High
patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4 months (3-4M),
and 6-10 months (6-10M).
E) Dot graph displaying the percentages of CD4+ Foxp3+CD25- T cells in
GVHD-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4
months (3-4M), and 6-10 months (6-10M).
F) Dot graph displaying the percentages of CD4+Foxp3+CD25+ T cells in
GVHD-High patients at baseline (BL), day 2 (D2), 1 month (1M), 3-4
months (3-4M), and 6-10 months (6-10M).
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Table 3.7. Summary of GVHD patients’ characteristics studied in this
chapter.

Parameters

GVHD Patients (n=7)

Disease

NHL (n=2)
CLL (n=3)
CML (n=1)
SLL (n=1)

Type of GVHD

Chronic GVHD (n=4)
Acute GVHD (n=2)
Overlap (n=1)

Donor

Match Related (n=4)
Match Unrelated (n=2)
Cord (n=1)

Organ affected

Skin (n=7)

Prophylaxis for GVHD

Tacrolimus +Methotrexate (n=5)

Concurrent Therapies

ECP + Tacrolimus (n=5)

Response
At 3 months
At 6 months
Longer Outcomes

PR (n=3); NR (n=2); SD (n=1); PD (n=1)
PR (n=5); PD (n=1); n/a (n=1)
Deceased (n=5); Alive (n=2)
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3.4. Discussion & Conclusions
In this small study of 9 L-CTCL patients with leukemic blood involvement
(L-CTCL) 6/9 or 66.7% were found to have a malignant T-reg phenotype cells
that correlated with the CD4+CD26- Sézary cell phenotype. Both populations of
cells decreased after ECP+BRM treatments suggesting that the treatments
favorably modulate peripheral blood levels of CD4+Foxp3+ T cells. All 6 of the L
CTCL patients whose blood had >80% CD4+Foxp3+ cells were also responders
to ECP-BRM. The other 3 patients did not have a malignant T-reg phenotype
and did not respond. We conclude that patients with malignant T-reg circulating
cells should be treated differently than patients whose blood has non-malignant
T-reg populations. ECP+BRM is an effective therapy for malignant T-reg L-CTCL
patients but may not be as effective in non-malignant T-reg L-CTCL patients.
Surprisingly, 5/7 GVHD patients had high CD4+Foxp3+ T cells at baseline
and 4/5 were responders. These data suggest that GVHD patients may have
had prior Foxp3+ pathogenic cells. We hypothesized that the initial disease
treated with transplantation may have been a malignancy of Foxp3+ T-regs. Two
of the 5 GVHD patients with high Foxp3 had Non-Hodgkin’s Lymphoma (NHL), 1
had Chronic Lymphocytic Leukemia (CLL), 1 had Chronic Myelogenous
Leukemia (CML), and 1 had Small Lymphocytic Lymphoma (SLL). All the GVHD
patients’ characteristics studied in this chapter are summarized in Table 3.7.
Although the literature is scarce, it has been reported that there is a high
frequency of T-regs in CLL patients and correlates with disease progression
[122]. Our data suggest that the high Foxp3 T-regs found in these GVHD High
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patients may be remanent of their initial disease prior to transplantation.
However, they may play a role in GVHD pathogenesis and may inhibit the graft
versus tumor effect. This data challenges the current thought that T-regs may be
beneficial for GVHD patients. Further studies are needed.
The immunosuppression in L-CTCL patients is attributed to many factors
but can be mainly explained by the loss of T- cell repertoire [59]. Having both
malignant clonal T cells that produce Th2 cytokines and T-reg type cells would
severely inhibit normal immune processes such as cell mediated cytotoxicity.
Although previous studies have found a lack of Foxp3 expression in L-CTCL
patients [70,71,120], Heid et al first reported that clonal tumor cells with
regulatory function express Foxp3 but lack CD25 typically found on CD4+ T-regs
in 40% of Sezary patients [73]. Our findings agree with Heid that L-CTCL or SS
tumor cells are Foxp3+CD4+ T cells lacking CD25, the alpha chain of the IL-2
receptor. CD25 is a widely accepted marker for T-regs, however, more recent
studies have reported that Foxp3 is a more specific marker for T-regs especially
for development of regulatory function. Foxp3-transduced into CD4+CD25- T
cells elicited suppression of T cell proliferation and autoimmune disease and
inflammatory bowel disease in vivo [123]. Another study characterized T-regs in
CD25-CD45RBlow CD4+ T cell population by Foxp3 expression and found their
suppressive activity in vitro was similar to CD4+CD25+ T –regs [124]. Taken
together, these studies indicate that expression of CD25 on CD4+ T cell is
insufficient to identify a cell as a T-reg and Foxp3 may be the more dominant
marker. Thus, heterogeneity amongst cells with suppressive function may exist.
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After ECP+BRM, 6 of 9 (66.7%) L-CTCL patients achieved clinical
responses confirming the efficacy of ECP reported by others [85,116]. L-CTCLHigh (n=7) had an 85.7% (6 of 7) response rate whereas L-CTCL-Low patients
had a 0% response rate. All the patients with >50% of CD4+Foxp3+ T cells that
were comparable to CD4+CD26- T cells responded to ECP+BRM. Responses to
ECP were associated with reduction in the numbers and percentages of
malignant CD4+ Foxp3+ T cells. Although a lower response rate was observed
in patients with a non-malignant Foxp3+ phenotype, their responses may be
attributed to other mechanisms. Increased cytotoxic activity may be responsible
for early responses seen in the patients with non-malignant Foxp3+ phenotype as
we observed an increase in numbers of CD8+IFN-γ+ T cells after 1 month of
treatment.
From these results, we found that patients can be divided into two groups:
one with high CD4+Foxp3+ T cells and a second with low CD4+Foxp3+ T cells.
Biological differences in these 2 cohorts suggest differences in treatment may be
warranted. Because Foxp3 may be a biomarker for malignancy in CTCL,
therapies targeting Foxp3 may be a novel treatment approach. Diagnostic tests
to detect Foxp3 expression should be incorporated into standard care to identify
patients with a T-reg phenotype. In addition, patients should be monitored for
treatment response by flow cytometry of peripheral blood instead of solely using
response observed in the skin. This study for the first time examines the
immunobiological effects of ECP+BRM in L-CTCL patients with a malignant T-reg
phenotype. It provides information to improve diagnosis and treatment of
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heterogeneous L-CTCL patients and suggest that L-CTCL patients with
malignant T-regs are better responders to ECP+BRM than patients without
malignant T-regs. ECP+BRM may be a good treatment option in patients with
malignant T-regs.
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CHAPTER 4
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON CYTOTOXIC T
LYMPHOCYTES IN PATIENTS WITH L-CTCL AND GVHD PATIENTS

4.1 Background and Rationale
Cytotoxic T lymphocytes (CTL) are a subset of T lymphocytes that arise
from common lymphoid progenitors differentiated from hematopoietic stem cells.
CTL by definition express the CD8+ molecule with the T cell receptor and kills
other immune cells. They have been of immunologic interest for potential
rejection of tumors and role in vaccination responses. CTL cytotoxic function
was first identified in 1968 using alloantigen-activated thymus derived cells [36].
After their initial discovery, further research revealed specificity of CTL [125].
This led to further exploration in vaccines where they may be induced to prevent
infectious diseases and limit tumor formation and progression.
At the molecular level, the cytotoxic function is mediated through
exocytosis of cytotoxic granules and cytokine secretion in response to MHC class
I antigenic peptides. By way of T cell receptor and CD8 ligand docking on the
target cell MHC class I+peptide, cytotoxic granules, perforin and granzymes,
participate in lysing and killing the target cell [42,125]. Perforin granules
perforate the cellular membrane first and then release granzymes into the target
cells. This also causes the activation of the CD8+ T lymphocyte which induces
the expression of CD69. This transmembrane C-type lectin protein is involved in
lymphocyte proliferation and is a receptor that transmits signals from outside to
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inside the lymphocyte [39,40]. The cytokine, interferon-gamma (IFN-γ), is
secreted in CD8+ T cells that have cytotoxic function [41,42]. IFN-γ is a type II
IFN that signals through the JAK-STAT pathway and helps to promote an
adaptive immune response against bacteria/viruses and tumors [43]. Thus, a
current method of identifying CTL by flow cytometry is by intracellular expression
of IFN-γ along with CD3, CD8, and CD69 markers [44-46].
Extracorporeal photopheresis, an immunomodulating therapy that induces
lymphocyte apoptosis by UVA-psoralen, is used to treat cutaneous T cell
lymphoma and graft-versus-host disease patients. ECP is hypothesized to have
an effect on CD8+ T cells in L-CTCL patients [108]. Prior to therapy, CD8+ T cells
are abnormally low and L-CTCL patients with close to normal levels of CD8+ T
cells do better on ECP [64]. Thus, it was hypothesized that ECP’s mechanisms
of action is by the engulfment of apoptotic cells by antigen-presenting cells to
induce or increase CTL and their activity [98]. However, in GVHD, CTL numbers
are elevated and are thought to be primary mediators of disease yet ECP is
clinically beneficial [112]. Thus, we hypothesize that ECP would decrease CTL
numbers and their activity in GVHD. Since it is currently unclear how ECP
modulates CTL, we investigated its effects on CD8+ T lymphocyte numbers and
their cytotoxicity in L-CTCL and GVHD patients.

4.2 Patients and Methods
Please refer to Chapter 7.
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4.3 Results
Patients and clinical responses
All L-CTCL (Table 2.1) and GVHD patients’ (Table 2.3) demographics and
characteristics are reported. The clinical characteristics and response rates of all
L-CTCL and GVHD are summarized in Table 2.2 and 2.4.
Based on sample availability, 6/18 L-CTCL patients and 3/11 GVHD
patients were analyzed for CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFN-γ+
T cells. The 6 L-CTCL patients’ demographics and characteristics are
summarized in Table 4.1. The 3 GVHD patients’ demographics and
characteristics are summarized in Table 4.2. The L-CTCL patients were
diagnosed with Sézary Syndrome with a T cell receptor clone present in 5/6
patients and one patient with late stage MF. There was 1 patient (pt.12) who had
a CD4+CD26+ T cell rather than CD4+CD26- population present. Patients’ ages
ranged from 58-79 years with a mean age of 70 years. There were more males
(n=4, 66.7%) than females (n=2, 33.3%) in this study. Five out of six patients
were concurrently on treatments with ECP. They were either on Bexarotene or
IFN-α or combination (Bexarotene+IFN-α). Two patients (pt. #1 and #3) were
treated with Bexarotene at the beginning of ECP treatment (study baseline). The
other patients had Bexarotene and/or IFN-α addition after 1 month of ECP
treatment except pt #4. Average number of ECP cycles at 6 months was 9.2
(range 7-12). All the GVHD patients had skin involvement. Two patients were
diagnosed with classic chronic GVHD and the other had late acute GVHD. Ages
ranged from 29-55 and the mean age was 45.3 years. There were more males
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(n=2; 66.7%) than females (n=1, 33.3%). GVHD patients were on combination
therapies including Tacrolimus. ECP cycles ranged from 25-37 at 6 months after
initial ECP treatment.
In SS patients, the blood responses measured by decreased CD4+CD26T cell numbers are as follows: CR (n=0), PR (n=0), MR (n=0), SD (n=5), and PD
(n=1). The skin responses measured by decreased mSWAT are as follows: CR
(n=0), PR (n=1), MR (n=2), SD (n=2), PD (n=1). The inclusion of skin and blood
responses resulted in overall responses as follows: CR (n=0), PR (n=1), MR
(n=2), SD (n=1), PD (n=2). Responders have CR, PR, MR, or SD. Response
rates were 83.3% for blood, 83.3% for skin, and 66.7% overall in SS patients.
The responses were graded in the disease affected skin as a regression
of erythroderma typical of cGVHD. The overall response rate in this study was
100% partial responders in GVHD patients. Clinical characteristics for L-CTCL
and GVHD patients are summarized in Table 4.3.
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Table 4.1. L-CTCL patients’ demographics and characteristics.
Pt.

Age/Sex/Race

Diagnosis

SWAT

CD4 CD26

TCR vβ

ECP

Concurrent

(%)

(%)

cycles

Therapies

64.2

n/a

7

Bexarotene,

+

#
1

58/F/C

SS IVA

63.0

-

IFN-α
2

79/M/C

SS IVB

54.0

87.5

(BM+)
3

71/M/C

SS/MF

78/F/AA

SS IVB

100.0

56.0

73/M/C

SS IVA

Bexarotene

Vβ 17

12

Bexarotene,

(94.0%)
47.0

94.5

(BM+)
5

10

(97.1%)

IVA
4

Vβ 13.6

Vβ 13.6

IFN-α
10

none

9

Bexarotene

7

Bexarotene

(95.0%)
47.0

77.1

Vβ 18.0
(95.0%)

6

61/M/C

SS IVB

87.0

91.7

Vβ 7.1
(97.0%)

Pt.= patient, F=Female, M=Male, C=Caucasian, AA=African American, ECP= Extracorporeal
Photopheresis, n/a=not available, BM=bone marrow,TCR=T cell receptor, SS=Sezary Syndrome,
MF=Mycosis Fungoides, IFN=interferon
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Table 4.2. GVHD patients’ demographics and characteristics.

Pt.

Age/

Disease

Type of

Type of

Organs

ECP

Concurrent

#

Sex/

Transplant

Donor

GVHD

affected

cycles

Therapies

Race

done

29/M/

CLL

Cord

Late

Skin (non-

25

Cellcept,

aGVHD

sclerodermoi

prednisone

d), GI (late

(80mg, 2x

aGVHD)

daily),

1

C

tacrolimus

2

52/M/

CML

C

Match

Classic

Skin

25

Steroids,

Related

cGVHD

(scleroder-

erythromycin,

transplant

(Progres-

moid, eyes,

prednisone

sive

liver, lung

(60mg)

cGVHD)

3

55/F/C

SLL

Match

Classic

Skin

37

Tacrolimus

Related

cGVHD-

(scleroderm-

(6mg), Medrol

Donor-

prior hx

oid), joints-

(16 mg)

from male

of

fasicitis,

donor

aGVHD

mouth, liver,
eye

GVHD=Graft versus Host Disease, aGVHD= acute GVHD, cGVHD=chronic GVHD, F=Female,
M=Male, C=Caucasian, ECP= Extracorporeal Photopheresis, n/a=not available, CLL=Chronic
lymphocytic leukemia, CML=Chronic myelogenous leukemia, SLL=Small Lymphocytic Lymphoma
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Table 4.3. Clinical summary of L-CTCL and GVHD patients.

Characteristic

L-CTCL (n=6)

GVHD (n=3)

Sex

Male (n=4, 66.7%)
Female (n =2, 33.3%)

Male (n=2, 66.7%)
Female (n=1, 33.3%)

Age (Mean)

70 (58-79) years

45.3 (29-55) years

Race

Caucasian (n=5)
African Amer. (n=1)

Caucasian (n=3)

Diagnosis

Sezary Syndrome IVA (n=3)

Late Acute GVHD (n=1)

Sezary Syndrome IVB (n=3)

Classic Chronic GVHD (n=2)

Tumor burden
(TB)

High TB (>1000/μl) 83.3%
Low TB (<1000 /μl) 16.7%

n/a

TCR vβ (≥95%)

Yes (n=5, 83.3%)

ECP cycles
after 6 mos
(Mean)

9.2 (7-12)

29 (25-37)

Clinical

SD (n=5, 83.3%)
PD (n=1, 16.7%)

PR (100%)

Bexarotene (n=5, 83.3%)
IFN-α (n=2, 33.3%)
Bexarotene+IFN-α (n=2, 33.3%)

Tacrolimus (100%)

n/a

Response
Combination
therapies
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Low levels of CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFN-γ+ T cells at
baseline in L-CTCL patients but high in GVHD patients
Absolute values of CD8+ T cells subsets were compared between normal
donors, L-CTCL, and GVHD patients at baseline prior to ECP treatment. The
absolute numbers of CD3+CD8+ T cells were statistically lowest (p<0.01) in LCTCL patients (n=6, 12.9±12.4 /μl) compared to normal donors (n=3, 596.6 ±
412.8 /μl). The highest absolute numbers were found in GVHD patients’ blood
(878.9 ± 1513.6 /μl) (Figure 4.1A). Similarly, CD3+CD8+CD69+ T cells were
lowest in L-CTCL patients (6.3±6.5 /μl) compared to normal donors (288.5 ±
185.6 /μl, p<0.01) and GVHD (758.8 ± 1314.0 /μl) patients (Figure 4.1B).
Interestingly, the CD3+CD8+IFN-γ+ T cells were also lowest in L-CTCL patients
(4.0 ±6.3) compared to normal donors (160.1±111.3, p<0.01) and GVHD patients
(456.9±791.2) (Figure 4.1C), (Table 4.4).
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Table 4.4. Baseline numbers of CD8+ T cell subsets in normal donors
and patients with L-CTCL and GVHD.
CD3 CD8

CD3 CD8 CD69

CD3 CD8 IFN- γ

(/μl)

(/μl)

(/μl)

Normal donor (n=3)

596.6 ± 412.8

288.5 ± 185.6

160.1±111.3

L-CTCL (n=6)

12.9±12.4

6.3±6.5

4.0 ±6.3

GVHD (n=3)

878.9 ± 1513.6

758.8 ± 1314.0

456.9±791.2

+

+

+
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+

+

+

+

+

ND

L-CTCL

GVHD

A

B

C

Figure 4.1
* p<0.01
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Figure 4.1. Flow cytometry dot plots and graphs of numbers of CD8+
T cell subsets before treatment.
A) CD3+CD8+ double positive T cells (top right quadrant) in a normal
donor (ND), L-CTCL #1, and GVHD patient #3. Graph (top right)
shows absolute numbers of CD3+CD8+ T cells in normal and
disease groups where black bars represent averages.
B) CD3+CD8+CD69+ triple positive T cells (top right quadrant) in a
normal donor (ND), L-CTCL , and GVHD patient. Graph (middle
right) shows distribution of absolute numbers of CD3+CD8+CD69+
T cells in normal and disease groups where the black bars
represent averages.
C) CD3+CD8+IFN-γ+ triple positive T cells (top right quadrant) in a
normal donor (ND), L-CTCL, and GVHD patient. Graph (lower
right) shows distribution of absolute numbers of CD3+CD8+IFN-γ+ T
cells in normal and disease groups where the black bars represent
averages.
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Increase in CD3+CD8+, CD3+CD8+CD69+, CD3+CD8+INF-γ+ T cells after ECP
treatment in L-CTCL patients
Five out of six L-CTCL patients had increased numbers of CD3+CD8+ and
CD8+CD69+ T cells after one month and 3 months to 1 year. On average,
CD3+CD8+ and CD3+CD8+CD69+ numbers spiked at Day 2 (117.3 ±187.8, 89.5
±146.0) and decreased after one month (101.7±196.6, 73.4±145.9) and 3 month1 year (60.3±123.3, 45.7±98.9). Numbers were still higher than baseline
(12.9±12.4, 6.3±6.5) after 3 months-1 year post-ECP (Figure 4.2A,B), (Table
4.5).
Four of the five patients with follow-up at one month had increased
CD3+CD8+ IFN-γ+ T cells from baseline. Three of the five patients with follow-up
at 3 months-1 year also had increased CD3+CD8+IFN-γ+ T cells from baseline.
On average, the numbers increased at Day 2 (7.8±7.4) and again at 1 month
(9.6±11.5) but were lower at 3 months-1 year (3.7±7.0) and almost back to
baseline levels (4.0±6.3) (Figure 4.2C), (Table 4.5).
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Table 4.5. Mean numbers of CD8+ T cell subsets pre- and post-ECP in LCTCL patients
Post-ECP

p-value

Pre-ECP

Day 2-1 week

1M

3M-1YR

CD3 CD8 (/μl)

12.9±12.4

117.3 ±187.8

101.7±196.6

60.3±123.3

0.02

CD3 CD8 CD69 (/μl)

6.3±6.5

89.5 ±146.0

73.4±145.9

45.7±98.9

0.02

CD3 CD8 IFN- γ (/μl)

4.0±6.3

7.8±7.4

9.6±11.5

3.7±7.0

0.02

+

+

+

+

+

+

+

+
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Figure 4.2
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Figure 4.2. Flow cytometry analysis of CD8+, CD8+CD69+, and CD8+IFN-γ+ T
cells in L-CTCL patients (n=6) at baseline and after ECP+BRM treatment.
Representative flow cytometry dot plots (left to right) from a responding L-CTCL
patient #1 and dot graphs of absolute numbers of (far right) A) CD3+CD8+, B)
CD8+CD69+, and C) CD8+IFN-γ+ T cells at baseline (BL), Day 2 (D2)-1week
(1W), 1 month (1M), and 3 months (3M)-1 year (1YR).
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CD3+CD8+, CD3+CD8+CD69+, CD3+CD8+IFN-γ+ T cells decreased in GVHD
patients treated with ECP
Three GVHD patients had follow-up time points at 3 months of ECP
therapy. All of them had decreased numbers of CD3+CD8+ and CD8+CD69+ T
cells from baseline (878.9 ±1513.6, 758.8±1314.0) to post –ECP 3 months
(1.8±2.4, 0.3±0.5). On average, the CD3+CD8+ T cell levels decreased from
baseline (878.9 ±1513.6) to day 2 (0.9±0.2) dramatically and remained low at 1
month (10.02) , 3 months (1.8±2.4), and 6 months (60.9) post-ECP. Similarly, on
average, the CD3+CD8+CD69+ T cell levels dramatically decreased from baseline
(758.8±1314.0) to day 2 ( 0.1±0.02) and remained low at 1 month (0.2), 3 months
(0.3±0.5), and 6 months (32.4) post-ECP.
CD3+CD8+IFN-γ+ T cells also decreased from baseline (456.9±791.1) to 3
months (0.2±0.2) post-ECP in all the GVHD patients. On average, the levels
dramatically decreased from baseline (456.9±791.1) to Day 2 (0.1±0.0) and
remained low at 1 month (0.08), 3 months (0.2±0.2), and 6 months (9.1) postECP (Figure 4.3, Table 4.6).

95

Table 4.6. Mean numbers of CD8+ T cell subsets pre- and post-ECP in
GVHD patients.

Post-ECP
Pre-ECP

Day 2

1 mo

3 mos

6mos

CD3+CD8+ (/μl)

878.9 ±1513.6

0.9±0.2

10.02

1.8±2.4

60.9

CD3+CD8+CD69+ (/μl)

758.8±1314.0

0.1±0.02

0.2

0.3±0.5

32.4

CD3+CD8+ IFN -γ+ (/μl)

456.9±791.1

0.1±0.0

0.08

0.2±0.2

9.1
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Figure 4.3
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Figure 4.3. Flow cytometry dot plots of numbers of CD8+ T cell subsets
after treatment in GVHD patient #3 who responded.
A) CD3+CD8+ double positive T cells (top right quadrant in each panel) at
baseline (BL), 3 months (mos), and 6 mos post-ECP (top from left to right).
B) CD3+CD8+CD69+ triple positive T cells (top right quadrant in each panel)
at BL, 3 mos, and 6 mos post-ECP (middle from left to right).
C) CD3+CD8+IFN-γ+ triple positive T cells (top right quadrant in each panel) at
BL, 3 mos, and 6 mos post-ECP (bottom from left to right).
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The correlation of CD3+CD8+IFN-γ+ T cells to clinical response in L-CTCL
patients
On average, the numbers of CD4+CD26- SS tumor cells decreased from
baseline (6281.8 /μl), to 1 month (4440.5 /μl), and to 6 months (2354.4 /μl) in
selected SS patients who had cells available for in vitro analysis (n=6). However,
numbers of CD3+CD8+IFN-γ+ T cells increased from baseline (3.99 /μl) to Day 2
(7.77/ μl) to 1 month (9.56 /μl), but then decreased at 3 months-1 year (3.69 /μl)
post-ECP (Figure 4.4A).
This change in CD8+ cells were associated with improvement and
worsening of skin involvement as determined by mSWAT measurements of skin
involvement. Mean mSWAT scores decreased from baseline (68.0), to 1 month
(45.7) but increased again at 3 months -1 year (54.3) in these SS patients (n=6).
There was an inverse relation between mSWAT improvement and increase in
numbers of CD3+CD8+IFN-γ+ T cells suggesting that induction of CD8+
cytotoxicity favorably effects clinical L-CTCL expression. (Figure 4.4B).
There were 3/6 responders within the SS patients studied for activated
and functional IFN-γ producing CD8+ T cells. Responding 3 patients had higher
numbers of CD3+CD8+ (23.7±3.5), CD3+CD8+CD69+ (11.5±2.8) and
CD3+CD8+IFN-γ+ (7.7±4.4) T cells prior to treatment compared to the three nonresponders (2.1±0.6; 1.2±0.5; 0.3±0.2) (Table 4.7). Although, in non-responders
there was an increase in numbers of CD8+ T cell subsets after treatment at 1
month, the numbers of CD3+CD8+ (Table 4.8, 9.0±1.2), CD3+CD8+CD69+ (Table
4.9, 4.5±1.2) and CD3+CD8+IFN-γ+ (Table 4.10, 2.2±0.8) remained low. In
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responders, the numbers of CD3+CD8+ (163.5±144.8, 6.9-fold, Table 4.8),
CD3+CD8+CD69+ (119.3±107.5, 10.3-fold, Table 4.9), and CD3+CD8+IFN-γ+
(14.5±7.5, 1.9-fold, Table 4.10) were higher than non-responders and increased
from baseline after only 1 month of ECP. These results suggest that although
these CD8+ subset numbers remained low, their activation status and cytotoxic
function improved with ECP treatment and may be related to overall clinical
response.
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Figure 4.4
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Figure 4.4. Clinical response and CD3+CD8+IFN-γ+ cytotoxic T cells in LCTCL patients.
A) Comparison of CD8+ IFN-γ+ T cells (dashed line) numbers to SS tumor
cells, CD4+CD26-, (solid line) T cell numbers before and after treatment.
B) Comparison of CD8+ IFN-γ+ T cells (dashed line) numbers mSWAT score
(solid line) before and after treatment.
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Table 4.7. Comparison of CD8+ T cells in L-CTCL responders and
non-responders at baseline.

Responders
(n=3)

Non-responders
(n=3)

CD3+CD8+

23.7±6.1

2.1±1.1

CD8+CD69+

11.5±4.8

1.2±0.9

CD8+IFN-γ+

7.7±7.7

0.3±0.3
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Table 4.8. Numbers of CD3+CD8+ T cells in L-CTCL responders
and non-responders before and after treatment.

BL
Responders (n=3)
1
27.2
11
27.2
18
16.7
Mean±SD 23.7±6.1

D2-1W

1M

3M-1YR

334.2
n/a

452.4
0.5

280.9
2.6

7.3
170.8±231.2

37.7
163.5±250.9

2.0
95.2±160.9

n/a
7.4
10.5
9.0±2.2

10.3
n/a
5.9
8.1±3.1

Non-Responders (n=3)
12
1.0
13
3.1
15
2.3
Mean±SD 2.1±1.1

n/a
10.5
n/a
10.5
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Table 4.9. Numbers of CD8+CD69+ T cells in L-CTCL responders and
non-responders before and after treatment.

Responders (n=3)
1
11
18
Mean±SD

BL

D2-1W

1M

8.3

258.1

333.8

222.6

17.1

n/a

0.3

0.2

9.2
11.5±4.8

4.7
131.4±179.2

23.8
119.3±186.1

0.1
74.3±128.4

Non-Responders (n=3)
12
0.2
13
1.8
15
1.5
Mean±SD
1.2±0.9
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3M-1YR

n/a

n/a

2.5

5.6

3.0

n/a

n/a
5.6

6.0
4.5±2.1

3.1
2.8±0.4

Table 4.10. Numbers of CD8+IFN-y+ T cells in L-CTCL responders
and non-responders before and after treatment.

BL
Responders (n=3)
1
0.6
11
15.8
18
6.6
Mean±SD

7.7±7.7

Non-Responders (n=3)
12
0.17
13
0.7
15
0.1
Mean±SD
0.3±0.3
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D2-1W

1M

3M-1YR

16.3
n/a
3.4

25.8
0.2
17.5

16.12
0.2
0.09

9.9±9.1

14.5±13.0

5.5±9.2

n/a
3.6
n/a
3.6

n/a
1.2
3.1
2.2±1.3

0.73
n/a
1.3
1.0±0.4

The correlation of CD3+CD8+IFN-γ+ T cells and clinical response in GVHD
patients
All three GVHD patients had decreased numbers of CD8+, CD69+ and
IFN-γ+ T cells and were classified as partial responders to ECP. Unfortunately,
there were not enough samples to assess the non-responders’ CD3+CD8+ T cells
levels and make a comparison.

4.4 Discussion & Conclusions
In this study, we report lower-than-normal baseline levels of CD3+CD8+,
CD3+CD8+CD69+, and CD3+CD8+IFN-γ+ T cells in the blood of Sézary Syndrome
(SS) patients. This is consistent with previous findings of low levels of
CD3+CD8+ T cells and their inability to produce IFN-γ cytokine in L-CTCL
patients [103,126,127]. There are no reported studies on the levels of
CD3+CD8+CD69+ or CD3+CD8+IFN-γ+ T cells in SS patients’ blood. However, in
GVHD patients, the levels of CD3+CD8+, CD3+CD8+CD69+, and CD3+CD8+IFNγ+ T cells were higher than normal at baseline which supports increased CD8+
Teffector cells in cGVHD patients reported by Grogan et al in 2011 [128]. ECP
action on CD8+ T cell subsets in L-CTCL and GVHD patients appear to have
opposite effects but how this occurs is unknown.
The major findings of this study are that CD3+CD8+, CD3+CD8+CD69+,
and CD3+CD8+INF-γ+ T cell numbers increase after ECP treatment in L-CTCL
patients but decrease in GVHD patients’ blood. Our data suggest that ECP is
improving not only the CD3+CD8+ T cell numbers but also their function as
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determined by increased IFN-γ secretion in L-CTCL patients’ blood CD8+ T cells
after 1 month of treatment. This increase was found in L-CTCL patients who
responded to ECP as measured by a decrease in the SS CD4+CD26- T cells and
by decrease in the skin mSWAT score. Surprisingly, the opposite effect occurred
in the blood of GVHD patients. Our results show that in GVHD patients,
CD3+CD8+ T cell numbers are not only reduced but also the function as
measured by IFN-γ is reduced by ECP. Since GVHD is mediated by CD3+CD8+
T cells, it is logical that the reduction of these cells would occur in patient
responders to ECP.
These results suggest for the first time that ECP works by different
mechanisms in improving L-CTCL and GVHD. This paradox suggests a
difference in ECP mechanism of action with different immunological states at
baseline. If ECP does not work the same way in these two diseases, it suggests
that ECP has differential effects on immunity and works by tailoring to the
immune disease state.
A possible mechanism by which ECP is modulating CD3+CD8+ T cells in
L-CTCL patients would be by antigen-presenting cell (APC) taking up
UVA/psoralen (ECP) treated cells that are apoptotic. This uptake of apoptotic
cells provides a tumor antigen source for activation of CD3+CD8+ T cells to
produce IFN-γ to elicit an anti-tumor immune response for down-regulation of
tumor cells in L-CTCL. Since previous studies in GVHD suggest that CD3+CD8+
T cells are mediators of disease, the decrease of these Th1 producing cells
would in turn cause disease regression in L-CTCL. Thus, the mechanism of this

108

reduction of cells by ECP in GVHD patients may be by regulatory T cell
suppression or cell death of CD3+CD8+ T cells by antigen-primed dendritic cells.
In summary, these results support our hypothesis that CD3+CD8+ T cells
are increased in numbers and activity in L-CTCL patients but are reduced in
GVHD patients after ECP treatment. This shows that the ECP mechanism of
action is different depending on the disease state. These findings are in a small
study cohort and were limited by amount of frozen patient samples available
before and after ECP. Although this study cohort was small, the majority of the
patients had similar trends. Another limitation of this study is that some of the
patients were on other treatments besides ECP. Therefore, it is unclear if the
induction of activated, IFN-γ producing CD3+CD8+ T cells were by ECP or by
Bexarotene or IFN-α. Thus, further study in a larger cohort with ECP as a
monotherapy in addition to the investigation of CTL activity would be ideal.
However, from this study we found for the first time a favorable increase in the
function of CD8+ T cells after only 1 month of ECP in L-CTCL patients whereas a
favorable decrease in numbers of functional CD8+ T cells in GVHD patients after
treatment with ECP. These data suggest that the mechanism of ECP action
through CD8+ T cells is different in L-CTCL and GVHD patients.
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CHAPTER 5
EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON DENDRITIC
CELLS IN PATIENTS WITH L-CTCL AND GVHD.

5.1 Background and Rationale
Like other immune cells that participate in the innate and adaptive immune
response, DCs express distinct cell surface receptors or ligands to sense and
respond to environmental stimuli. These cell surface signaling molecules (CSSM
s) are vital for their differentiation, maturation, and function [129]. In the normal
steady-state condition, DCs express low levels of CSSMs such as co-stimulatory
and/or co-inhibitory molecules and MHC Class I and II molecules. This allows the
immature DCs to maintain peripheral tolerance to self-antigens. In the presence
of danger signals (i.e. antigens and infections), there is an up-regulation of
expression of CSSMs resulting in DC maturation and subsequently promoting T
cell immunity [130]. The B7 family members including B7-1 (CD80), B7-2
(CD86), and B7-H2 (the inducible costimulator ligand, ICOSL) are major
members of CSSMs. They provide T-cell costimulatory/coinhibitory signals upon
binding to their receptors CD28, CTLA-4 and ICOS, respectively [131].
DCs are the most important initial source of cytokines governing the
development of helper T cell (Th) responses. Two well described human DC
subpopulations with different biological functions are: the CD11c+CD123- myeloid
DCs (mDCs) and the CD11c-CD123+ plasmacytoid DCs (pDCs), which induce
different types of Th cell responses based on environmental factors [8]. In
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general, mDCs produce IL-12 and polarize naïve T cells toward a Th1
phenotype, whereas pDCs stimulated with IL-3 produce low levels of IL-12 and
large amounts of IFN-α and results in a Th2 response. Moreover, ICOSL on
pDCs is critical for inducing the immunosuppressive IL-10 cytokine which induces
T-regs [8]. The up-regulation of Th1 cytokines and IL-12 is present in chronic
GVHD and implicates a Th1-driven immunopathogenesis [132]. Modulation of
DC subpopulations and a shift of cytokine profile from Th1 to Th2 in chronic
GVHD patients have been observed following treatment with ECP [133]. In
contrast, the impaired immunity in L-CTCL has been attributed to the overproduction of Th2 cytokines secreted by the malignant T cell clone(s) and downregulation of Th1 and cytotoxic responses [134]. Moreover, the low baseline
mDCs and pDCs found in SS patients are associated with increased tumor
burdens and advanced stages of L-CTCL [68]. Others have shown that the
clinical and hematological Improvements are associated with a shift from Th2 to
IL-12 and Th1 response in SS patients after ECP treatment [108]. We therefore
postulated that the paradoxical effects of ECP in L-CTCL and GVHD might be
explained if ECP were to modulate DC subpopulations in both diseases.
In this prospective study, we studied the prevalence of mDCs and pDCs in
peripheral blood by flow cytometry in 18 L-CTCL patients and 11 GVHD patients
during ECP treatment. HLA-DR (MHC class II) and co-stimulatory/co-inhibitory
molecules were assessed by flow cytometry and quantitative real-time PCR. We
conclude that ECP modulates DC subpopulations’ numbers, ratios, and
expression of CSSMs. The correction of DC defects and balancing of DCs
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towards a more normal status may contribute to the clinical efficacy of ECP in LCTCL and GVHD.
5.2. Patients & Methods
Please refer to Chapter 7.
5.3. Results
Low numbers of DC subpopulations in GVHD and L-CTCL patients increase
after ECP
Since defective blood DCs in L-CTCL and GVHD patients are thought to
contribute to impaired immunity [68,135], we first determined the prevalence of
Lin-HLA-DR+CD11c+ mDC and Lin-HLA-DR+CD123+ pDC in L-CTCL and GVHD
patients at baseline and after ECP treatment.
When compared to the numbers of mDC (0.64±0.15%) and pDC
(0.68±0.50%) from normal donors (ND), GVHD patients had significantly lower
numbers of both mDCs (0.10±0.11%, p<0.05) and pDCs (0.08±0.12%, p<0.01) at
baseline (Table 5.1 & Figure 5.1A). In contrast, DC numbers in L-CTCL patients
were much more heterogeneous at baseline: 12 of 18 (66.7%) L-CTCL patients
had lower than normal mDCs (0.24±0.16%, p<0.01) and 10 of 18 (55.6%) had
lower than normal pDCs (10/18, 0.13±0.05%, p<0.01) (Table 5.2). Those LCTCL patients with low pDCs also had low numbers of mDCs.
One third of L-CTCL patients had normal DC counts (5/18, 27.8%, mDCs;
7/18, 38.9%, pDCs). Our data suggest that loss of mDCs and pDCs is profound
in GVHD patients, and commonly occurs in L-CTCL patients.
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Patient #17 with a T-reg phenotype, reported elsewhere [136], had high
mDC and normal pDC numbers. Clinically his skin looked normal but contained
on biopsy atypical lymphocytes with epidermotropism consistent with MF. We
hypothesized that the T-reg phenotype may suppress the inflammatory response
causing characteristic MF erythema and scaling. Patient #4 with high pDCs and
normal count mDCs had the lowest tumor burden (20.6% CD4+CD26- circulating
T cells) among all patients.
After ECP treatment, there was a trend towards increasing numbers of
mDCs and pDCs over 1-6 month period in 6 GVHD patients (Figure 5.1B,
Figure 5.2B&D). Similarly, 8 of 12 L-CTCL patients (66.7%) with low mDCs at
baseline showed an increase in mDC numbers over 6 months of ECP treatment
(Figure 5.1C, Figure 5.2A). Four of 5 (80.0%) L-CTCL patients with normal
mDC numbers before ECP also showed an increased in mDC numbers with
therapy. Patient#17 with a T-reg phenotype had high mDCs before ECP which
increased even more after treatment. On the other hand, 7 of 18 (38.9%) LCTCL patients had increased pDCs and 8 patients had decreased pDCs (44.4%)
(Figure 5.1C, Figure 5.2C). In half of the L-CTCL patients with low pDC
numbers before ECP, pDC numbers increased at 3 and 6 months after ECP (5 of
10, 50.0%). Four of 7 (57.1%) L-CTCL patients with normal baseline pDC
numbers had decreased numbers during therapy. Patient #4 with high pDCs
before ECP had lower numbers after ECP. Overall, in L-CTCL patients, the
average mDC number was significantly increased at 6 months after ECP (p =
0.0272) and the average DC number was marginally lower at 3 months after ECP
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compared to baseline (p = 0.0944) (Table 5.3). Our results suggest that after
ECP, in GVHD patients, there is a trend towards increasing numbers of both
mDCs and pDCs, whereas in most of L-CTCL patients there was a selective
increase of mDCs and heterogeneous changes in the pDC numbers.
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Table 5.1. Percentage, ratio, and HLA-DR expressions on mDCs and pDCs
in peripheral blood of L-CTCL and GVHD patients

Percentages (%)

ND
(n=3)
GVHD
(n=10)
L-CTCL
(n=18)

Ratio

mDC

pDC

mDC/pDC

pDC/mDC

0.64 ± 0.15

0.68 ± 0.50

1.34 ± 1.26

1.35 ± 1.08

0.1 ± 0.11*

0.08 ± 0.12**

5.66 ± 4.55*

0.46 ± 0.52*

0.41 ± 0.32*

0.39 ± 0.48

1.39 ± 0.94

1.05 ± 0.79

HLA-DR expression (MFI)†
mDC

pDC

3956.41 ±

1860.10 ±

1398.29

602.57

2006.65 ±

1466.11 ±

1157.27**

674.18

1919.62 ±

1460.78 ±

965.76**

609.11

†MFI: mean fluorescence intensity; ND: normal donors;* p<0.05; ** p<0.01
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Table 5.2. The numbers, ratios, and HLA-DR expression on mDCs and
pDCs in L-CTCL patients

Percentages (%)

Ratio

HLA-DR
expression (MFI)†

mDC

pDC

mDC/pDC

pDC/mDC

mDC

pDC

1

1

3

3

0

0

1.33

2.12

3.04±0.58

2.68±0.18

-

-

L-CTCL-High
No. of patients
value
L-CTCL–Normal
No. of patients
Value

5

7

15

14

2

9

0.65±0.08

0.50±0.16

1.06±0.57

0.76±0.27

3851.68

2007.42

±9.19

±498.81

L-CTCL-Low
No. of patients
Value

12

10

0

1

16

9

0.24±0.16

0.13±0.05

-

0.27

1678.11
±702.52

984.16
±199.66

L-CTCL–High: L-CTCL patients with higher than normal levels; L-CTCL–Normal: L-CTCL patients with
normal range levels; L-CTCL–Low: L-CTCL patients with lower than normal levels; †MFI: mean fluorescence
intensity
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Figure 5.1
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Figure 5.1. Flow cytometry analysis of Lin-HLA-DR+CD11c+ mDCs and LinHLA-DR+CD123+ pDCs in L-CTCL and GVHD patients before and after ECP.
A) Freshly isolated PBMCs from normal donors (ND), L-CTCL patients, and
GVHD patients were stained with 4-Color Dendritic Value Bundle kit, and LinHLA-DR+CD11c+ mDC populations (upper panel, circled purple portions) and LinHLA-DR+CD123+ pDC populations (lower panel, circled green portions) were
gated with Becton-Dickinson LSR II (BD Biosciences, San Jose, CA), and
analyzed in FCS Express Version 3 (DeNovo software, Los Angeles, CA). The
representative flow plots from ND, GVHD patients, and L-CTCL patients with
normal (L-CTCL-Normal) and low (L-CTCL-Low) counts were shown.
B) The representative flow plots of Lin-HLA-DR+CD11c+ mDCs (upper panel) and
Lin-HLA-DR+CD123+ pDCs (lower panel) were presented from GVHD patient #3
at baseline (BL), Day 2, 1M, and 3M after ECP.
C) The representative flow plots of Lin-HLA-DR+CD11c+ mDCs (upper panel) and
Lin-HLA-DR+CD123+ pDCs (lower panel) were from L-CTCL Patient #11 at BL,
Day 2, 1M, 3M, and 6M after ECP.
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Figure 5.2
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Figure 5.2. Changes in numbers of Lin-HLA-DR+CD11c+ mDCs and LinHLA-DR+CD123+ pDCs in GVHD and L-CTCL patients before and after ECP.
Freshly isolated PBMCs from L-CTCL patients and GVHD patients were stained
using 4-Color Dendritic Value Bundle kit and analyzed by flow cytometry for LinHLA-DR+CD11c+ mDCs and Lin-HLA-DR+CD123+ pDCs.
A) Percentages of Lin-HLA-DR+CD11c+ mDCs of PBMCs in L-CTCL
patients at BL, Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.
B) Percentages of Lin-HLA-DR+CD11c+ mDCs of PBMCs in GVHD
patients at BL, Day 2, 1M, 3/4 M, and 6/7 M after ECP.
C) Percentages of Lin-HLA-DR+CD123+ pDCs of PBMCs in L-CTCL
patients at BL, Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.
D) Percentages of Lin-HLA-DR+CD123+ pDCs of PBMCs in GVHD
patients at BL, Day 2, 1M, 3/4 M, and 6/7 M after ECP. The dotted
lines were linear trend lines of change. *Linear mixed model analysis,
P value: <0.05.
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Table 5.3. Changes in numbers, ratios, and the expressions of HLA-DR on
DC subpopulations in all L-CTCL patients treated for 6 months with ECP.

BL

Day 2

1M

3/4 M

6 /7M

p-value

mDC(%)

0.41

0.46

0.31

0.53

0.70

0.0272

pDC(%)

0.39

0.48

0.30

0.24

0.34

0.0944

mDC/pDC

1.39

1.26

1.41

2.29

2.27

0.0313

pDC/mDC

1.05

1.10

1.12

0.80

0.81

0.4600

HLA-DR on mDC

1919.62

2185.08

1939.03

2115.20

1887.15

0.0815

HLA-DR on pDC

1460.78

1403.75

1300.20

1531.65

1348.87

0.0380*

*: Wilcoxon analysis: the HLA-DR on pDC at 6/7M was significantly lower than baseline in
non-responders.
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Ratios of mDCs and pDCs in GVHD and L-CTCL patients are favorably
altered after ECP
Human mDCs and pDCs induce different types of Th responses
depending on environmental factors [8,137]. Skewing of cytokine profiles towards
Th2 in L-CTCL and towards Th1 in GVHD are thought to associate partially with
the distinct defects of mDCs and pDCs[133], [68]. Therefore, we next
determined whether ratios of mDCs and pDCs were affected by ECP.
Compared to ND (1.34±1.26; 1.34±1.08), GVHD patients possessed
higher mDC/pDC ratios (5.66±4.55, p<0.05) and lower pDC/mDC ratios
(0.46±0.52, p<0.05, Table 5.1). This mDC predominance is consistent with the
immunopathogenesis of GVHD as a Th1 mediated process. In contrast, 15 of 18
(83.3%) L-CTCL patients had normal ratios of mDC/pDC (1.06±0.57) and 14 of
18 (77.8%) L-CTCL patients had normal ratios of pDC/mDC (0.76±0.27) (Table
5.2). Three L-CTCL patients had higher than normal mDC/pDC ratios (#11, #15
& #17; 3.04±0.58, p<0.05), and 3 patients (#4, #5 & #13) had higher than normal
pDC/mDC ratios (2.68±0.18, p<0.05). Patient #17 with a Treg phenotype was the
only L-CTCL patient manifesting a low pDC/mDC ratio (0.27) and a high
mDC/pDC ratio (3.71). Among all L-CTCL patients, responders had relatively
higher mDC/pDC ratios on average compared to non-responders at baseline, but
the differences were not significant (1.60±0.90 versus 0.98±0.94, p=0.231,Table
5.3). These data suggest mDC predominance in GVHD at baseline, but
relatively balanced DC ratios in most L-CTCL patients despite low DC numbers.
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Six GVHD patients with complete samples showed a continuous decrease
in the mDC/pDC ratios during therapy (BL: 5.66±4.55; Day 2: 4.41±3.56; 1M:
2.95±3.05; 3/4 M: 2.62±3.06; and 6/7 M: 0.48, Figure 5.3C). Conversely, they
also had increasing pDC/mDC rations (BL: 0.46±0.52; Day 2: 0.65±0.79; 1M:
0.59±0.36; 3/4 M: 0.72±0.40; and 6/7 M: 2.08, Figure 5.3D). This supports the
use of ECP as an immunosuppressive therapy inducing Th2 immune response to
dampen Th1 mediated GVHD.
In contrast, L-CTCL patients’ mDC/pDC ratios increased over the course
of therapy with decreased ratios of pDC/mDC, regardless of clinical responses
(Figure 5.3A &B). These trends continued up to 9~12 months after the initial
ECP treatment in 4 patients who remained on therapy. In L-CTCL patients with
normal baseline mDC/pDC ratios, the ratio continued to increase in 11 of 15
(73.3%) while the ratio of pDC/mDC decreased. In 2 of 3 patients with high
mDC/pDC ratios at baseline, the mDC/pDC ratios decreased over therapy and in
3 of 3 patients with high pDC/mDC ratios at baseline, their ratios decreased after
ECP (3/3, 100%). Overall, over the course of ECP therapy the average
mDC/pDC ratio in L-CTCL patients significantly increased from baseline to 3/4
months and 6/7 months (P value = 0.0313), and the pDC/mDC ratio decreased,
but not significantly (Table 5.3). These data suggest that ECP may work
differently in L-CTCL versus GVHD by favoring mDC predominance in L-CTCL
while shifting mDC to pDC predominance in GVHD (Figure 5.3E&F).
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Figure 5.3
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Figure 5.3. Changes in the ratios of mDCs and pDCs in GVHD and L-CTCL
patients before and after ECP. Freshly isolated PBMCs from L-CTCL patients
and GVHD patients were stained using 4-Color Dendritic Value Bundle kit and
analyzed by flow cytometry for Lin-HLA-DR+CD11c+ mDCs and Lin-HLADR+CD123+ pDCs.
A) The ratio of mDCs versus pDCs (mDC/pDC) in L-CTCL patients at BL,
Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.
B) The ratio of pDCs versus mDCs (pDC/mDC) in L-CTCL patients at BL,
Day 2, 1M, 3/4 M, 6/7 M, and 9-12M after ECP.
C) The ratio of mDC/pDC in GVHD patients at BL, Day 2, 1M, 3/4 M, and
6/7 M after ECP.
D) The ratio of pDC/mDC in GVHD patients at BL, Day 2, 1M, 3/4 M, and
6/7 M after ECP. The dotted lines were linear trend lines of changes. *:
Linear mixed model analysis, P value: <0.05.
E) The average of mDC/pDC ratio in L-CTCL (-♦-) versus GVHD (--) at
BL and after ECP. (F) The average of pDC/mDC ratio in L-CTCL (-♦-)
versus GVHD (--) at BL and after ECP.

126

Low HLA-DR expression on mDCs and pDCs in GVHD and L-CTCL patients
is altered after ECP
As mentioned previously, DCs undergo a maturation process through
increasing HLA-DR expression [129]. To determine the maturation status, we
then evaluated the levels HLA-DR expression by flow cytometry on DCs before
and after ECP treatment in GVHD and L-CTCL patients’ blood.
The HLA-DR expression on mDCs was significantly lower in both GVHD
and L-CTCL patients at baseline (MFI: 2006.65±1157.27 and 1919.62±965.76,
Table 5.1) than in normal donors (3956.41±1398.29, p<0.01). Sixteen of 18 LCTCL patients had lower than normal HLA-DR expression on mDCs
(1678.11±702.02 MFI, p<0.01, Table 5.2). HLA-DR levels on pDCs in both
GVHD and L-CTCL patients were similar to each other and slightly lower
(1466.11±674.18 and 1495.74±642.70) than normal donors (1860.10±602.57,
p>0.05). Half of L-CTCL patients had lower than normal HLA-DR expression in
pDC at baseline (984.16.11±199.66 MFI, p<0.01). These data suggest that
mDCs are immature in most GVHD and L-CTCL patients, and pDCs are
immature in half of L-CTCL patients before therapy.
GVHD patients maintained a low expression of HLA-DR on mDCs and
pDCs after ECP treatment. In contrast, in L-CTCL patients, HLA-DR expression
was up-regulated on mDCs after ECP. Ten of 16 (62.5%) L-CTCL patients with
low HLA-DR expression on mDCs had higher levels at 6 months after ECP and 8
of the 10 were responders (80.0%). However, 3 of 6 non-responders had
decreased HLA-DR expression on mDCs (3 down, 2 up, 1 no change). At 6
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months after ECP, 7 of 9 (77.8%) with low baseline HLA-DR expressions on
pDCs also were found to have increased levels with 6 of 7 responders (85.7%).
But, 4 of 6 non-responders had decreased expression of HLA-DR on their pDCs.
The HLA-DR expression on pDC at 6/7 months in non-responders was
significantly lower than baseline (P value = 0.0380, Table 5.3). These results
suggest that ECP not only modulates the DC numbers, but also regulates
expression of HLA-DR which may reflect their maturity and ability to present
antigens to T cells.
HLA-DR and costimulatory/coinhibitory molecules mRNA expressions in LCTCL and GVHD are modulated by ECP
To further assess the maturation status of DCs, we examined mRNA
expressions of HLA-DR and costimulatory/coinhibitory molecules in PBMCs
isolated from blood of L-CTCL and GVHD patients. As indicated in Figure 5A,
both L-CTCL and GVHD patients’ PBMCs had low mRNA expression of HLA-DR
at baseline which was consistent with our flow cytometry findings. Low mRNA
levels of ICOS and ICOSL were also detected within PBMCs in both diseases but
were much lower in GVHD patients. Expression of CD28, CTLA-4, CD80, and
CD86 mRNA were higher than normal in L-CTCL, but lower than normal in
GVHD patients. After 6 months of therapy, increased HLA-DR and decreased
CTLA-4 mRNA levels were seen in both diseases (Figure 5.4B & C). Following
ECP therapy, in GVHD patients, ICOSL levels increased by 17-fold, from -33.6 at
baseline to -16.3 at 6 month (Figure 5.4B). Three L-CTCL patients who
responded to ECP had higher levels of CD86 mRNA (responder: 1.12, versus
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non-responder: -1.02; rank sum p <0.05) or lower levels of CTLA-4 (responder:
3.86, versus non-responder: 5.67, rank sum p <0.05) at baseline (Table 5.4).
After ECP, responders also had higher levels of HLA-DR, CD80, and CD86
mRNA compared to non-responders (Figure 5.4C & D). These data suggest
that ECP may modulate the expression of costimulatory /coinhibitory molecules
which may affect DC maturation and function in L-CTCL and GVHD patients,
respectively.
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Figure 5.4
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Figure 5.4. Expression of HLA-DR and costimulatory/coinhibitory molecule
mRNA in GVHD and L-CTCL patients at baseline and 6 months of ECP.
Total RNA was extracted from PBMCs, and the first strand cDNA was
synthesized with RT2 First Strand Kit. Relative mRNA levels of HLA-DR, CD28,
CD80, CD86, CTLA-4, ICOS, and ICOSL were assessed with RT2 Profiler
Human T-cell Activation PCR Array using ABI Prism 700 Sequence Detection
System. The fold changes relative to GAPDH were calculated as the levels of
gene expression, and calibrated with normal donors.
A) Relative fold changes at BL in L-CTCL versus GVHD patients.
B) Relative fold changes at BL versus 6M after ECP in GVHD
patients.
C) Relative fold changes at BL versus 6 M after ECP in L-CTCL
responders (R).
D) Relative fold changes at baseline versus 6 M after ECP in L-CTCL
non-responders (NR). *: Rank sum analysis, p<0.05.
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Table 5.4. Comparison of baseline parameters in L-CTCL responders and
non-responders
Parameters
Responders (n=12)
Non-responders (n=6)
P value
Age
66.5 (58.0 – 79.0)
71.0(54.0 – 78.0)
0.332
ECP cycles
9.4 (6.0 -15.0)*
9.2 (6.0 – 12.0)
0.889
BSA
61.9 (5.0 – 89.0)
71.1 (37.5 – 100.0)
0.315
SWAT
65.2 (5.0 – 100.0)
72.2 (47.0 – 100.0)
0.247
CD4+CD26- tumor cells (%)
0.054
82.3 (64.2 – 94.7)
66.3 (20.6 – 94.5)
Flow cytometry analysis
mDC (%)
0.43 ± 0.35
0.39 ± 0.29
0.803
pDC (%)
0.30 ± 0.23
0.56 ± 0.78
0.305
mDC/pDC
1.60 ± 0.90
0.98 ± 0.94
0.231
pDC/mDC
0.89 ± 0.68
1.37 ± 0.97
0.386
HLA-DR in mDC (MFI)
1722.43 ± 917.42
2314.00 ± 1019.59
0.199
HLA-DR in pDC (MFI)
1369.81 ± 621.54
1642.73 ± 593.30
0.231
QT-PCR array (fold
change)**
HLA-DR
-1.01
-1.19
> 0.05
CD28
11.02
9.68
> 0.05
< 0.05
CTLA-4
3.86
5.67
CD80
1.43
1.50
> 0.05
< 0.05
CD86
1.12
-1.02
ICOS
-1.54
-1.55
> 0.05
ICOSL
-6.56
-6.81
> 0.05
*: Patient#8 is not included
**: relative fold change compared to normal donor. Data from 3 responders and 3 non-responders
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5.4 Discussion & Conclusions
The findings of increased mDC numbers, increased mDC/pDC ratios, and
up-regulation of CD80, CD86, and HLA-DR expression in two thirds of L-CTCL
patients after ECP treatment suggest that ECP treatment is associated with a
favorable mDC modulation in patients with L-CTCL. Upregulation of mDC and
Th1 cytokines would be expected to improve the Th2 profile of the malignant Tcells. Another possibility is that reduction of malignant cells by apoptosis which
would decrease levels of Th2 cytokines could also favorably affect the mDC ratio.
On the other hand, increased pDC/mDC ratios and up-regulation of ICOSL
found in three fourths of GVHD patients suggest that ECP treatment in this Th1
mediated disease is associated with a favorable pDC upregulation in patients
with GVHD leading to a switch from Th1 to Th2 cytokine profiles. Two thirds of
L-CTCL patients and all GVHD patients had some degree of reduced levels of
mDC and pDC numbers at baseline that resulted in imbalanced ratios of mDCs
and pDCs. Costimulatory/coinhibitory molecules expressed in L-CTCL and
GVHD in opposite directions are favorably regulated after ECP in this study.
Although L-CTCL and GVHD have opposite immune-pathogenesis, following
ECP therapy there are changes of DC numbers, ratios, and expression of
costimulatory/coinhibitory molecules in a favorable direction in each disease. We
conclude that the normalization of DC defects and balancing of DCs towards a
more normal status by ECP may underlie its efficacy in L-CTCL and GVHD
patients.
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The impaired cellular immunity in L-CTCL patients is attributed to several
factors, one of which is reduced DC populations leading to reduction of IL-12/Th1
cytokine secretion and a weakened anti-tumor response. Wyosocka et al. first
reported the defect in circulating DCs in SS patients,[68] and found that profound
defects of both mDCs and pDCs were correlated to high tumor burdens. Our
findings are consistent with their study in that the majority of our L-CTCL patients
with > 50% circulating CD4+CD26- tumor cells had decreased mDCs and pDCs
at baseline. Only one patient (Pt#4) with an intermediate tumor burden had
normal DC counts. It was reported that pDCs synergize with mDCs in the
induction of antigen-specific antitumor immune responses in an experimental
melanoma mice model [138]. In this study, we found that L-CTCL patients with
low numbers of pDCs also had low mDC numbers, and patients who had
relatively normal pDCs tended to have normal mDC counts. Our data suggest
that a synergistic interaction between mDCs and pDCs may exist in our L-CTCL
patients.
After ECP treatment, the numbers of mDCs were increased in most LCTCL patients but changes in the numbers of pDCs were less pronounced. The
mDC numbers were increased significantly at 3 and 6 months after ECP with the
highest numbers found at 6 months when clinical responses were most
pronounced. The selective increase in mDC numbers after ECP in L-CTCL
patients is hypothesized to shift DC subpopulations towards a mDC
predominance. These results suggest that ECP has a sustained effect on mDCs.
The source of increased mDCs after ECP treatment is unknown. They could
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migrate from the bone marrow, or could have an extended life span, or could
derive from tissue monocytes.
The maturation status characterized by the expression of CSSMs on DCs
is critical for induction of immune responses or immune tolerance [129,130].
After ECP, apoptotic lymphocytes are phagocytosed by macrophages and DCs,
and thought to send “danger signals” to the immune system. A transcriptome
study of L-CTCL showed that genes associated with DC differentiation, adhesion,
maturation, and activation(CD40,CD80, and DC-LAMP) were increased in ECPtreated cells ex vivo [139]. Our study consistently showed that CD80, CD86, and
HLA-DR expression was up-regulated and CTLA-4 was down-regulated after
ECP in L-CTCL patients. Different from their ex vivo study, our study was the
first to monitor DC kinetic changes in vivo in patients’ circulation while they were
undergoing ECP over a 6 month period. Change in mDC numbers along with upregulation of HLA-DR and co-stimulatory molecules may enhance mDC
maturation and activity, and further boost anti-tumor immune responses that are
thought to be therapeutic for L-CTCL. This type of immune regulation would be
expected to exacerbate patients with GVHD.
Previous studies reported that ECP modulates DC populations in patients
with GVHD[139-141],[133],[142]. ECP induces a shift from mDCs to pDCs,
together with a shift from a predominantly Th1 cytokine profile to a Th2 cytokine
profile in GVHD patients [133]. Consistent with these ex vivo studies, our study
found that ECP did favorably affect DC subpopulations in GVHD patients in vivo.
Before ECP treatment, there were low numbers of both mDCs and pDCs in
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GVHD patients with a severe deficiency in pDC numbers resulting in an mDC
predominant status. After ECP treatment, both DC subpopulations were
increased in most GVHD patients. Of note, the pDC numbers increased more
than mDC numbers resulting in an increased pDC/mDC ratio or an mDC to pDC
shift. This agrees with one prior study reported a decreased mDC numbers in
GVHD patients after ECP [133]. Differences between our study and theirs may
due to our mixed acute and chronic GVHD patient group, in vivo assessment,
and different combinations of immunosuppressive therapies.
As mentioned before, IL-3 stimulation of pDCs induces a Th2 response,
and could also induce T-reg [8]. A recent study reported that monocyte-derived
DCs in co-culture with ECP-treated PBMCs produce increased quantities of IL10, and the co-cultured DCs expressed reduced CD40 and CD86 following
stimulation with LPS [142]. Our study did not show much change in CD86
expression, but we did find significant upregulation of ICOSL mRNA expression
in PBMCs of GVHD patients. The expression of ICOSL on pDCs is critical for
inducing IL-10-producing Treg and immune tolerance [8],[143]. Thus, our results
suggest that ECP could induce a shift from mDCs to pDCs in GVHD patients in
vivo, and this change along with an increase of ICOSL may enhance pDC
activity, and further promote a Th2 response and immune tolerance to allo- or
auto-reactivity.
The extent of immune stimulation depends not only on the maturation
state of DCs, but also on the local cytokine milieu. In a pro-inflammatory
environment, DCs undergo maturation and the effector immune responses are
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amplified. In contrast, in the absence of suitable inflammation, immune tolerance
develops toward the acquired antigen. Clinical and hematological improvements
after ECP in SS patients are associated with a shift from Th2 phenotype to an
increase of IL-12/Th1 phenotype [108]. A shift of the cytokine profile from Th1 to
Th2 by ECP in GVHD have already been observed [133]. Therefore, we
hypothesize that in L-CTCL, ECP treatment not only recruits more circulating
mDCs, but also creates a pro-inflammatory environment for DCs to mature and
be activated. In the presence of the costimulatory molecules, CD80 and CD86,
these DCs are capable of presenting tumor antigens from phagocytosed tumor
cells in the context of MHC molecules and thus initiating favorable cellular
immune responses [144]. In contrast, in GVHD, more pDCs are recruited to the
peripheral blood favoring the expansion of Th2 clones and secretion of IL-4 and
IL-10. When DCs present antigens to T cells in the absence of the costimulatory
molecules, T-cell anergy or tolerance to transplants or auto-tissues may arise
[130,133,145]. Our working model is that ECP restores impaired immunity in
these two diseases by multiple effects including elimination of the pathologic Tcell populations (Th2 clone in L-CTCL and Th1 clone in GVHD), modulation of
the cytokine milieu, and correction of DC defects (Figure 5.5).
In this study, we found high variability in DC numbers, ratios, and HLA-DR
and costimulatory/coinhibitory molecule expression among L-CTCL patients at
baseline, suggesting a heterogeneous, complex immunopathogenesis.
In summary, this translational research study suggests that ECP alone or
ECP with immunomodulatory therapy favorably modulate DC subpopulations in
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vivo in both L-CTCL and GVHD patients. This modulation could underlie and
explain the favorable effects of ECP for both diseases. Clinical studies
investigating the effect of IL-12 and DC vaccine in L-CTCL patients depend on
enhancing DC functions have also been successful [146-148]. Strategies to
activate DCs are attractive to enhance insufficient immune responses in patients
with infectious diseases and cancers or can be used as well to attenuate
excessive immune responses in allergy, autoimmunity and transplantation [149].
This study for the first time assesses DC changes in both L-CTCL and GVHD
patients groups in parallel. It provides further insight into how ECP could
effectively treat two immunological diseases with nearly opposite
immunopathogenesis.
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Figure 5.5
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Figure 5.5. The working model of immunologic mechanism of ECP action
on L-CTCL and GVHD patients. Along with the shift of cytokine milieu; ECP
could effectively balance DC subpopulation towards a more normal status in
patients with L-CTCL and GVHD. In L-CTCL, ECP treatment not only recruits
more circulating mDCs, but also creates a pro-inflammatory environment for DCs
to mature and be activated. In the presence of the costimulatory molecules,
CD80 and CD86, these DCs are capable of presenting tumor antigens from
phagocytosed tumor cells in the context of MHC molecules and thus initiating
favorable cellular immune responses. In contrast, in GVHD, more pDCs are
recruited to the peripheral blood favoring the expansion of Th2 clones and
secretion of IL-4 and IL-10. When DCs present antigens to T cells in the
absence of the costimulatory molecules, T-cell anergy or tolerance to transplants
or auto-tissues may arise.
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CHAPTER 6
SUMMARY & DISCUSSION
6.1 Summary of Chapter 2: Efficacies of extracorporeal photopheresis in
patients with L-CTCL and GVHD in this study.
In this study, ECP+BRM was clinically effective in L-CTCL and GVHD
patients as measured by regression of disease in skin or blood. We confirmed
the published efficacy of ECP for the treatment of patients with both L-CTCL and
GVHD. Our overall response rate was 66.7% in 12 of 18 patients with L-CTCL
on ECP+BRM and 54.5% in 6 of 11 GVHD patients treated with ECP plus
immunosuppressive therapies. Of interest, 4 of 6 (66.7%) L-CTCL patients who
received ECP alone and 8 of 12 (66.7%) who received ECP with
immunomodulatory therapy achieved the same overall clinical response rate.

6.2 Summary of Chapter 3: Effect of extracorporeal photopheresis on
regulatory T cells in L-CTCL
In our study, we found in L-CTCL that CD4+CD26- tumor cells correlated
with percentages of CD4+Foxp3+ and CD4+ Foxp3+CD25- T cells, suggesting that
tumors cell may have the T-reg phenotype. At baseline, seven L-CTCL patients
had high CD4+Foxp3+ T cells (L-CTCL-High, 85.5±20.8%) and 2 patients had low
CD4+Foxp3+ T cells (L-CTCL-Low, 1.4±1.1%). Six of the 7 L-CTCL-High patients
had similar percentages of CD4+Foxp3+ T cells and CD4+CD26- tumor T cells.
After ECP treatment at 3 months, we found that the percentages of tumor cells
as well as percentages of Foxp3+ T cells decreased in L-CTCL-High patients.
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The L-CTCL-Low patients initially had low CD4+Foxp3+ T cells which remained
low after treatment. In the GVHD patients, there were 5 patients with high
CD4+Foxp3+ T-regs (GVHD-High, 90.5±5.7%), 1 Low CD4+Foxp3+ T-regs
(GVHD-Low, 0.07%), and 1 normal CD4+Foxp3+ T-regs (GVHD-normal, 10.3%).
In GVHD-High patients, there was a decrease of CD4+Foxp3+ and
CD4+Foxp3+CD25- T cells by increase in CD4+Foxp3+CD25+ T cells and 4/5
patients responded.
This data suggest that ECP may work better in L-CTCL patients with a
tumor CD4+Foxp3+ T-reg phenotype compared to patients whose tumor cells are
not of the T-reg phenotype. In GVHD patients, the high CD4+Foxp3+ T cells may
be remanent of intial disease. This suggests that Foxp3 is a possible molecule
for development of targeted therapies.

6.3 Summary of Chapter 4: Effect of extracorporeal photopheresis on
cytotoxic T lymphocytes in L-CTCL and GVHD patients
Since the numbers and percentages of CD8+ T cells are extremely low in
L-CTCL patients and cellular cytotoxicity is impaired, CD8+ cytotoxic T
lymphocytes (CTLs) are hypothesized to also be low and impaired. As expected,
we found abnormally low levels of CD8+, CD8+CD69+, and CD8+IFN-γ+ T cells in
6 available L-CTCL patients prior to treatment. After treatment, CD8+,
CD8+CD69+, and CD8+IFN-γ+ T cell numbers increased. In addition, CD8+IFN-γ+
T cells increased in number after 1 month of treatment in patients whose
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peripheral blood showed decreases in CD4+CD26- cells tumor cells, suggesting
that cellular cytoxicity was improving.
In GVHD patients, it was expected that CD8+ T cells were high at baseline
because GVHD is mediated by CD8+ cytotoxic cells. After treatment, CD8+,
CD8+CD69+, and CD8+IFN-γ+ T cells decreased. The decreases in the CD8+ T
cells show that ECP is favorably down-regulating cellular mediated immunity
against host targets in GVHD patients.

6.4 Summary of Chapter 5: Effect of extracorporeal photopheresis on
dendritic cells in L-CTCL and GVHD patients
We confirmed the DC defect in L-CTCL and GVHD patients as
percentages and numbers of mDCs and pDCs were abnormally low prior to
treatment. After treatment, the mDCs and pDCs increased suggesting that the
DC compartment was defective but not completely impaired. In addition to the
increase in mDCs and pDCs, HLA-DR, and CSSMs also increased on mDCs and
pDCs in some L-CTCL and GVHD patients. The increase of HLA-DR and
CSSMs suggest that the DCs are maturing and becoming activated. When ratios
of mDCs to pDCs were examined after treatment, it was noted that mDCs
predominated in L-CTCL patients whereas pDCs predominated in GVHD
patients. These findings suggest that ECP may work differently in L-CTCL and
GVHD patients. Depending on the environment, DCs differentiate into subsets
that elicit appropriate immune responses. ECP may work by modulating the DC
compartment towards predominance of mDCs that induce Th1 responses in L-
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CTCL patients and pDCs that induce an immunosuppressive Th2 response in
GVHD patients, explaining how one treatment may improve both diseases.
Further in vitro studies to test mDCs and pDCs functions and differentiation in the
L-CTCL and GVHD setting are needed.

6.5 Overall Discussion
From this study, we confirmed that ECP is clinically efficacious in L-CTCL
and GVHD patients. At the cellular level, mDCs, pDCs, and CTLs were
modulated in L-CTCL and GVHD patients after ECP+BRM treatment. In L-CTCL
patients, mDCs and CTLs increased whereas in GVHD patients, pDCs increased
while CTLs decreased. These findings support our hypothesis and indicate that
the mechanism of ECP action is different in L-CTCL and GVHD patients.
An unexpected finding was that L-CTCL patients fell into two separate groups
based on CD4+Foxp3+ T cells. Six of 9 patients had >80% of Foxp3+ T-regs
which correlated with the percentages of tumor cells while the other 3 patients
had tumors that did not correlate with T-regs. All 6 patients with tumor T-regs
responded whereas the other 3 patients without tumor T-regs did not respond.
ECP+BRM appears to be more effective in the patients with Foxp3+ malignant
phenotype cells compared to the patients without the Foxp3+ malignant
phenotype.
We are the first to identify these cellular changes in patients in vivo and
compare between L-CTCL patients versus GVHD patients in relation to clinical
response. These data impact not only the clinical aspects of L-CTCL and GVHD,
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but also translate into a better understanding of L-CTCL and GVHD pathology for
advancement of the fields. The increase of mDCs and pDCs in L-CTCL and
GVHD, respectively, indicate that the differential DC modulation with a positive
clinical response suggest that these DCs are capable of improving disease
according to the immune milieu. The identification of these specific DC subsets
in these patients shows that the diseased immune system is capable of returning
to baseline and provides information on what cellular pathway ECP is beneficially
modulating. The induction of mDCs and CTLs with a positive clinical response in
L-CTCL patients suggest that ECP is beneficially working on these cells. The
enhancement of these cells can possibly lead to complete responses or
remission. Addition of biological modifiers such as cytokines, IFN-γ or IL-12, with
ECP can target mDCs and/or augment CTLs in L-CTCL patients. Because we
observed cellular changes at specific timepoints, addition of biological modifiers
at timepoints of change may enhance the later response. For example, we
observed that CTLs were immediately increased after 24 hours of ECP and
increased the highest at 1 month then decreased at 3 and 6 months of treatment
in L-CTCL patients. The early increase of CTLs may need to be sustained at
later timepoints to achieve complete responses. Thus, addition of biological
modifiers to enhance CTLs at 1 month after initial ECP could be beneficial.
After the 1 month timepoint, CTLs decreased in L-CTCL patients. The
decrease of CTLs may be attributed to T-reg suppression. Therefore, to
enhance CTLs, T-regs could be down-regulated with anti-Foxp3 therapy or antiPD1 antibody which has been shown to target T-regs and mask the T-reg
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inhibition of CTLs in melanoma patients [150]. Conversely, in GVHD patients,
efforts to increase T-regs and decrease CTLs would be beneficial. Addition of
anti-CTLA-4 antibody with ECP may expand Foxp3+ T-regs to suppress the
unwanted CTLs [151].
Surprisingly, we found a subset of L-CTCL patients with a tumor T-reg
population. This finding shifts the paradigm thought that tumors are not T-regs in
L-CTCL patients. Tumor T-reg patients were also found to be better responders
to ECP compared to patients without a tumor T-reg population.
Since the tumor T-reg patients achieved a better response rate compared to nonT-reg patients, these findings suggest that ECP is a good treatment modality in
this subset of patients whereby cells may be more sensitive to ECP. We are the
first to identify that tumor T-reg patients are better responders to ECP compared
to non-tumor T-reg patients.
The interesting finding that T-regs are tumor cells in a subset of L-CTCL
patients can help to better diagnose, treat, and improve quality of life. Since
Foxp3 is currently a unique identifier for T-regs, it can be used as a biomarker.
Use of Foxp3 in diagnostic tests should be incorporated with standard tests to
identify these unique patients to tailor the treatment regime. By utilizing Foxp3
during diagnosis and tracking response by Foxp3, can improve the outcome of
these tumor T-reg patients.
To address the intriguing question of “Is the mechanism of ECP same or
different in L-CTCL versus GVHD patients, we conclude that the mechanism(s)
of ECP action is different in GVHD versus L-CTCL patients. Although ECP
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modulated the DCs in both disorders, the favorable increases of mDCs in LCTCL patients and pDCs in GVHD patients suggest that these DC subsets may
be orchestrating opposite T cell responses which is dependent on the disease
milieu.
In GVHD patients, the mechanism of ECP action may be through
immunoregulation by regression of cytotoxic CD8+ T cells and balancing of
immunity. The increase of pDCs after ECP treatment in our study patients
suggest that the pDCs may be orchestrating an opposite T cell response or Th2
response to balance out the pathogenic Th1 immunity. The decrease of
cytotoxic CD8+ T cells in the GVHD patients supports this mechanism and
increases of T-regs which suppress CD8+ T cells may be occurring.
In contrast, in L-CTCL patients, the mechanism of ECP may be through
immunostimulation by improved anti-tumor cyotoxicity. The vaccination theory of
ECP action proposed that ECP induces maturation of monocyte-derived DCs that
injest ECP treated tumor cells, present tumor antigen to CD8+ T cells, and
induces cytotoxic T lymphocytes to attack tumor cells. While this mechanism
may be occurring in these L-CTCL patients undergoing ECP treatment, we found
that the CD8+ lymphocyte numbers and percentages remained low despite the
increase after ECP. However, the lack of dramatic increase in CD8+ T cell
numbers does not rule out a role for CD8+ T cells in function or cytotoxicity
against tumor cells after ECP treatment. Further studies are necessary.
Because we found a unique subset of L-CTCL patients with malignant Tregs and they responded better to ECP+BRM compared to the patient cohort
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without tumor T-regs, we hypothesized that the mechanism of action through the
regression of malignant T-regs could be not only through the vaccination
mechanism, but also T-reg plasticity and increased sensitivity of tumor T-regs to
ECP. Since T-regs in the normal state have developmental plasticity whereby
they can change into other Th17 or Th cells in the appropriate setting [152], the
tumor T-reg decrease may be due to the increase of other Th cell types or the
tumor T-regs may be changing into other types of cells. It would be interesting to
determine the origin of these tumor T-reg cells. Whether the tumor cells may
have evolved into T-regs or the T-regs became malignant could be a subject of
future study for therapeutic potential.
Another avenue for potential therapy for L-CTCL patients rely on the
characteristics of these tumor T-regs. These tumor T-regs may have more
sensitivity towards ECP treatment which may be due to their unique cellular and
molecular characteristics. The tumor T-regs may provide a better anti-tumor
response because of the increased expression of certain antigens that can
mediate a strong anti-tumor cyototoxic attack. The expression of Foxp3 provides
a biomarker and possible target for therapy in this subset of L-CTCL patients.
Foxp3 can be used to diagnose patients as well as serve as a marker of clinical
response to therapies. Exactly what features make tumor T-regs more sensitive
to treatment may need to be further investigated.
Thus, we propose that the mechanism of ECP action in L-CTCL and
GVHD patients are different and depend on the immune milieu. Although DCs
are modulated in both diseases, the T cell responses are different. The
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mechanism of ECP action in L-CTCL patients may be through immunostimulation
by induction of cytotoxic CD8+ T cells whereas the mechanism of ECP action in
GVHD patients may be through immunosuppression by regression of cytotoxic
CD8+ T cells and possible induction of T-regs (Figure 6.1). Future studies are
needed to monitor T-regs in GVHD patients undergoing treatment, to investigate
the cytokine milieu before and after ECP, and to discover specific antigens that
may improve responses to ECP for the ultimate goal of improving the lives of
patients treated with ECP.
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Figure 6.1
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Figure 6.1. Proposed immunological mechanisms of ECP in L-CTCL and
GVHD patients.
A) ECP can modulate cytokines by shifting the Th1 cytokines dominance
to Th2 cytokines in clinically responsive GVHD patients [153].
Improvement of CTCL is associated with shift of Th2 cytokines
predominance to Th1 cytokines [108].
B) Dendritic cells are modulated by ECP. DCs can differentiate from
monocytes into myeloid DCs (mDCs) and plasmacytoid DCs (pDCs)
within the plastic treatment apparatus depending on immune milieu.
The differences in immune milieu in CTCL and GVHD induce mDCs
and pDCs, respectively.
C) MDCs induce an immunostimulatory T cell response through
induction of CD8+ cytotoxic T lymphocytes for anti-tumor immunity in
CTCL patients.
D) PDCs induce an immunosuppressive T cell response through induction
of CD4+ regulatory T cells for anti-inflammatory reactions to ameliorate
GVHD, autoimmune disorders, and transplantation rejection.
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CHAPTER 7
PATIENTS AND METHODS

7.1 Study design and patients.
Patients with L-CTCL and GVHD starting ECP treatment signed written
informed consents to enroll in this study between 2007 and 2010. This study
was conducted according to the Declaration of Helsinki Principles and the study
protocol was approved by the University of Texas M D Anderson Cancer Center
Institutional Review Board. The ISCL/EORTC revised criteria for MF and SS was
used for staging and classification.[154] MF/SS patients were recruited based on
blood involvement or >50% CD4+CD26- circulating Sézary cells. All patients
were starting ECP for the first time and were treated with the UVAR XTS
photopheresis system (Therakos, Inc. Raritan, NJ). ECP was administered over
2 consecutive days every 2 to 4 weeks per cycle for L-CTCL patients and weekly
for GVHD patients. Fresh blood was collected before ECP (baseline) and after
ECP on Day 2 (D2), 1 month (1M), 3 months (3M), and 6 months (6M). Buffy
coats from normal donors (ND) were obtained from the Department of
Transfusion Medicine at our institution.
7.2 Clinical Responses.
Clinical responses for L-CTCL patients were assessed at 6 months after
ECP by one expert clinician (MD). Extent of disease in each body surface area
(BSA) was calculated and multiplied by 2 for plaques and multiplied by 4 for
tumors to obtain the modified skin-weighted assessment (mSWAT).[154] The
mSWAT was performed for each patient at enrollment and every visit. Peripheral
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blood CD4+CD26- or CD4+CD7- T-cells were identified as the circulating tumor
cells by flow cytometry [121,148,155,156] The clinical responses for L-CTCL
patients were based on the percentage changes of skin scores and circulating
tumor cells as described in other clinical trials with modification [154,157-159].
The changes in SWAT were calculated as [(SWAT score from baseline – SWAT
score at 6 months)/ SWAT score from baseline × 100]. The tumor cell changes
were calculated as [(CD4+CD26- circulating T cells from baseline – CD4+CD26circulating T cells at 6 months)/ CD4+CD26- circulating T cells from baseline ×
100] [157-159]. Patients with complete responses (CR) were ones who cleared
all skin or blood involvement. Partial responses (PR) were defined as >50%
improvement in skin or blood involvement. Minor responses (MR) were defined
as 25%-50% skin or blood improvement. Patients with CR, PR and MR were
grouped as responders. Non-responders included patients with stable disease
(SD) whose skin or blood changes were within 25% from baseline, and patients
with progressive disease (PD) who had 25% worsening skin or blood
involvements from baseline. The clinical responses for GVHD patients were
assessed by an experienced hematologist (AA), and the detailed response
criteria for GVHD patients were referred to those used by our institution.[160]
7.3 Blood Samples.
Peripheral mononuclear cells (PBMCs) were isolated by density gradient
centrifugation from whole blood. Freshly isolated PBMCs were characterized for
myeloid and plasmacytoid dendritic cells by flow cyotometry. Slowly
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cryopreseved PBMCS were analyzed for CD4+Foxp3+ T cell subsets and CD8+ T
cell subsets by immunofluorescence flow cytometry.
7.4 Immunofluorescence and intracellular flow cytometry analysis of
Foxp3+ CD4+ T lymphocyte subsets.
Thawed PBMCs were incubated with CD3-APC/Cy7 (Biolegend), CD4FITC (BDBiosciences), and CD25-PE/Cy7 (Biolegend) immunofluorescence
antibodies on ice for 30 minutes. Cells were washed with FACS Buffer (Miltenyi
Biotech) twice prior to intracellular Foxp3 detection. A fixation/permeabilization
buffer from the Foxp3 detection kit (eBioscience) was incubated with PBMC for
35 minutes at 40 C. Cells were then washed with a 1X perm/wash buffer
(eBioscience) prior to incubation with Foxp3-PE antibody (clone PCH101) for 30
minutes at 40 C. After incubation, cells were washed twice with 1X perm/wash
buffer. Reference counting beads were added to each sample (Spherotech).
Cells were run on a Gallios flow cytometer (Beckman Coulter) and analyzed on
Kaluza (Beckman Coulter) software as per manufacturer’s instructions.
Percentages of CD4+Foxp3+, CD4+CD25-Foxp3+, CD4+CD25+Foxp3+ T cells
were calculated out of CD4+ T cells. Absolute numbers were calculated on the
ratio of cell counts over bead counts multiplied by the ratio of known bead
numbers and volume.
7.5 Immunofluorescence and intracellular flow cytometry analysis of CD8+
T cell lymphocyte subsets.
Thawed PBMC were activated with Leukocyte Activation Cocktail, with BD
GolgiPlug (BDBiosciences) for 3 hours at 37oC. After activation, the cells were
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treated with the Live/Dead Fixable Dead Cell stain kit (Invitrogen) for 30 minutes
at room temperature. Cells were then incubated with CD3-FITC (BD
Biosciences), CD8-APC (Biolegend) immunofluorescence antibodies for 30
minutes on ice. Cells were washed with FACS Buffer (Miltenyi Biotech) twice
prior to intracellular CD69 detection. A BD Cytofix/Cytoperm™
Fixation/Permeabilization Solution Kit (BD Bioscience) was used to fix and
permeabilize PBMC for 20 minutes at 40 C. Cells were then washed with a 1X
perm/wash buffer (BD Bioscience) twice prior to incubation with CD69-PerCyPCy
5.5 (Biolegend) antibody for 30 minutes at 40 C. After incubation, cells were
washed twice with 1X perm/wash buffer. Cells were then washed with a 1X
perm/wash buffer (BD Bioscience) twice prior to incubation with IFN-γ –PE (R&D
Systems) antibody for 30 minutes at 40 C. Reference counting beads
(Spherotech) were added prior to flow cytometry. Cells were run on a Gallios
flow cytometer (Beckman Coulter) and analyzed on Kaluza (Beckman Coulter)
software as per manufacturer’s instructions. Percentages of CD3+CD8+,
CD3+CD8+CD69+ and CD3+CD8+ IFN-γ + T cells were calculated out of
CD3+CD8+ T cells. Absolute numbers were calculated based the ratio of cell
counts over bead counts multiplied by the ratio of known bead numbers and
volume. Numbers of unactivated cell subsets were compared to activated cell
subsets.
7.6 Immunofluorescence flow cytometry analysis of myeloid and
plasmacyotid dendritic cells.
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Lin-HLA-DR+CD11c+ mDCs and Lin-HLA-DR+CD123+ pDCs were
analyzed using 4-Color Dendritic Value Bundle kit (BD Biosciences, San Jose,
CA) by immunofluorescence flow cytometry. Freshly isolated PBMCs were
stained with the following antibodies: Lineage Cocktail 1-FITC (Lin 1) (anti-CD3,
CD14, CD16, CD19, CD20, and CD56), anti-HLA-DR-PerCP, anti-CD123-PE,
and anti-CD11c-APC, for 30 minutes on ice. Cells were washed and fixed before
subjected to flow cytometry analysis. Mouse IgG1-PE and IgG2a-APC were
used as isotype controls. The Lin-HLA-DR+CD11c+ mDC and Lin-HLADR+CD123+ pDC portions were gated with Becton-Dickinson LSR II (BD
Biosciences, San Jose, CA), and the acquired data were analyzed in FCS
Express Version 3 (DeNovo software, Los Angeles, CA). The percentages,
ratios, and the mean fluorescence intensity (MFI) of HLA-DR expression of
mDCs and pDCs were calculated for all samples.
7.7 Quantitative real-time PCR of Foxp3 mRNA expression.
Total RNA was extracted from PBMCs with Rneasy Mini kit (Qiagen,
Valencia, CA). The first strand cDNA was synthesized from 400ng of total RNA
with an oligo (dT) 12–18 primer using RT2 First Strand Kit (Qiagen, Valencia,
CA). The relative mRNA levels Foxp3 were assessed using ABI Prism 700
Sequence Detection System (Applied Biosystems Inc. Foster City, CA). Preformulated TaqMan primer and probe mixes for Foxp3 (Hs00203958) were used
(Applied Biosystems, Foster City, CA). The fold changes relative to the
endogenous control gene, glyceraldehyde 3-phosphate dehydrogenase
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(GAPDH), were calculated as the levels of gene expression, and calibrated with
normal donors.
7.8 Quantitative real-time PCR for expression of CSSMs mRNA.
Total RNA was extracted from PBMCs with RNeasy Mini kit (Qiagen,
Valencia, CA). The first strand cDNA was synthesized from 400ng of total RNA
with an oligo (dT) 12–18 primer using RT2 First Strand Kit (Qiagen, Valencia,
CA). The relative mRNA levels of HLA-DR, CD28, CD80, CD86, CTLA-4, ICOS,
and ICOSL were assessed with RT2 Profiler Human T-cell Activation PCR Array
(SABiosciences, Frederick, MD) using ABI Prism 700 Sequence Detection
System (Applied Biosystems Inc. Foster City, CA). SYBR Green-optimized
primers and pre-formulated PCR master mix were used. The fold changes
relative to GAPDH were calculated as the levels of gene expression, and
calibrated with normal donors.
7.9 Statistical analysis of CD4+ and CD8+ T cell subsets.
Each parameter was calculated for mean ± standard deviation. Statistical
significance of percentages and numbers of CD4+Foxp3+, CD4+CD25+Foxp3+,
CD4+CD25-Foxp3+, CD3+CD8+, CD8+CD69+, and CD8+IFN-γ+ between L-CTCL
patients and normal donors, between the 2 L-CTCL patients groups, and
between baseline and time points after ECP-BRM treatment were determined by
the student’s T-test and Wilcoxon Rank sum analysis. P-values less than 0.05
were considered as significantly different between the experimental groups. Fold
changes of greater or less than 2-fold was significantly different in gene
expression. A correlation was determined by Pearson product-moment
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correlation coefficient R ≥0.5-1.0 based on the Cohen scale. Statistical analyses
were evaluated in Microsoft Office Excel 2007 and PASW Statistics 17.0. Graph
Pad Prism and Microsoft Office Excel 2007 were used to design figures.
7.10 Statistical analysis of Dendritic cell subsets.
Each parameter (percentage, ratio, and MFI) was summarized using the
mean (standard deviation) and median (range). The levels at baseline and the
changes from baseline for each time point were computed. The linear mixed
models were used assess the changes (from baseline) as a function of time point
and clinical response (PR+MR versus PD+SD). We started with the full model
with fixed effect of time point, response status, and their interaction, as well as a
random effect of patients. We sequentially eliminated the interaction and the
main effect of response in absence of significant effect. Statistical significance of
percentages, ratios, and MFI of HLA-DR expression in mDCs and pDCs between
L-CTCL patients and GVHD patients, between normal donors and patients, and
between baseline and different time points after ECP were assessed. The
statistical significance of fold changes of each gene mRNA level between patient
response groups and before and after ECP was determined by the student’s Ttest and Wilcoxon Rank Sum statistical analysis. Differences between
experimental groups were considered significant if the p value was less than
0.05. Differences in gene expression were also considered meaningful if the fold
regulations were more or less than 2-fold. Statistical analyses were conducted
using SAS 9.2 for Windows (Copyright @ 2011 by SAS Institute Inc., Cary, NC)
and Microsoft Office Excel 2007.
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